La maladie de Parkinson au Canada (serveur d'exploration)

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Neuroferritinopathy: Pathophysiology, Presentation, Differential Diagnoses and Management

Identifieur interne : 000179 ( Pmc/Corpus ); précédent : 000178; suivant : 000180

Neuroferritinopathy: Pathophysiology, Presentation, Differential Diagnoses and Management

Auteurs : Niraj Kumar ; Philippe Rizek ; Mandar Jog

Source :

RBID : PMC:4795517

Abstract

Background

Neuroferritinopathy (NF) is a rare autosomal dominant disease caused by mutations in the ferritin light chain 1 (FTL1) gene leading to abnormal excessive iron accumulation in the brain, predominantly in the basal ganglia.

Methods

A literature search was performed on Pubmed, for English-language articles, utilizing the terms iron metabolism, neurodegeneration with brain iron accumulation, and NF. The relevant articles were reviewed with a focus on the pathophysiology, clinical presentation, differential diagnoses, and management of NF.

Results

There have been nine reported mutations worldwide in the FTL1gene in 90 patients, the most common mutation being 460InsA. Chorea and dystonia are the most common presenting symptoms in NF. There are specific features, which appear to depend upon the genetic mutation. We discuss the occurrence of specific mutations in various regions along with their associated presenting phenomenology. We have compared and contrasted the commonly occurring syndromes in the differential diagnosis of NF to guide the clinician.

Discussion

NF must be considered in patients presenting clinically as a progressive movement disorder with variable phenotype and imaging evidence of iron deposition within the brain, decreased serum ferritin, and negative genetic testing for other more common movement disorders such as Huntington’s disease. In the absence of a disease-specific treatment, symptomatic drug therapy for specific movement disorders may be used, although with variable success.


Url:
DOI: 10.7916/D8KK9BHF
PubMed: 27022507
PubMed Central: 4795517

Links to Exploration step

PMC:4795517

Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">Neuroferritinopathy: Pathophysiology, Presentation, Differential Diagnoses and Management</title>
<author>
<name sortKey="Kumar, Niraj" sort="Kumar, Niraj" uniqKey="Kumar N" first="Niraj" last="Kumar">Niraj Kumar</name>
<affiliation>
<nlm:aff id="aff1">
<addr-line>Department of Clinical Neurological Sciences, Western University, London, ON, Canada</addr-line>
</nlm:aff>
</affiliation>
</author>
<author>
<name sortKey="Rizek, Philippe" sort="Rizek, Philippe" uniqKey="Rizek P" first="Philippe" last="Rizek">Philippe Rizek</name>
<affiliation>
<nlm:aff id="aff1">
<addr-line>Department of Clinical Neurological Sciences, Western University, London, ON, Canada</addr-line>
</nlm:aff>
</affiliation>
</author>
<author>
<name sortKey="Jog, Mandar" sort="Jog, Mandar" uniqKey="Jog M" first="Mandar" last="Jog">Mandar Jog</name>
<affiliation>
<nlm:aff id="aff1">
<addr-line>Department of Clinical Neurological Sciences, Western University, London, ON, Canada</addr-line>
</nlm:aff>
</affiliation>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">PMC</idno>
<idno type="pmid">27022507</idno>
<idno type="pmc">4795517</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4795517</idno>
<idno type="RBID">PMC:4795517</idno>
<idno type="doi">10.7916/D8KK9BHF</idno>
<date when="2016">2016</date>
<idno type="wicri:Area/Pmc/Corpus">000179</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000179</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en" level="a" type="main">Neuroferritinopathy: Pathophysiology, Presentation, Differential Diagnoses and Management</title>
<author>
<name sortKey="Kumar, Niraj" sort="Kumar, Niraj" uniqKey="Kumar N" first="Niraj" last="Kumar">Niraj Kumar</name>
<affiliation>
<nlm:aff id="aff1">
<addr-line>Department of Clinical Neurological Sciences, Western University, London, ON, Canada</addr-line>
</nlm:aff>
</affiliation>
</author>
<author>
<name sortKey="Rizek, Philippe" sort="Rizek, Philippe" uniqKey="Rizek P" first="Philippe" last="Rizek">Philippe Rizek</name>
<affiliation>
<nlm:aff id="aff1">
<addr-line>Department of Clinical Neurological Sciences, Western University, London, ON, Canada</addr-line>
</nlm:aff>
</affiliation>
</author>
<author>
<name sortKey="Jog, Mandar" sort="Jog, Mandar" uniqKey="Jog M" first="Mandar" last="Jog">Mandar Jog</name>
<affiliation>
<nlm:aff id="aff1">
<addr-line>Department of Clinical Neurological Sciences, Western University, London, ON, Canada</addr-line>
</nlm:aff>
</affiliation>
</author>
</analytic>
<series>
<title level="j">Tremor and Other Hyperkinetic Movements</title>
<idno type="eISSN">2160-8288</idno>
<imprint>
<date when="2016">2016</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc>
<textClass></textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">
<sec>
<title>Background</title>
<p>Neuroferritinopathy (NF) is a rare autosomal dominant disease caused by mutations in the ferritin light chain 1 (
<italic>FTL1</italic>
) gene leading to abnormal excessive iron accumulation in the brain, predominantly in the basal ganglia.</p>
</sec>
<sec>
<title>Methods</title>
<p>A literature search was performed on Pubmed, for English-language articles, utilizing the terms iron metabolism, neurodegeneration with brain iron accumulation, and NF. The relevant articles were reviewed with a focus on the pathophysiology, clinical presentation, differential diagnoses, and management of NF.</p>
</sec>
<sec>
<title>Results</title>
<p>There have been nine reported mutations worldwide in the
<italic>FTL1</italic>
gene in 90 patients, the most common mutation being 460InsA. Chorea and dystonia are the most common presenting symptoms in NF. There are specific features, which appear to depend upon the genetic mutation. We discuss the occurrence of specific mutations in various regions along with their associated presenting phenomenology. We have compared and contrasted the commonly occurring syndromes in the differential diagnosis of NF to guide the clinician.</p>
</sec>
<sec>
<title>Discussion</title>
<p>NF must be considered in patients presenting clinically as a progressive movement disorder with variable phenotype and imaging evidence of iron deposition within the brain, decreased serum ferritin, and negative genetic testing for other more common movement disorders such as Huntington’s disease. In the absence of a disease-specific treatment, symptomatic drug therapy for specific movement disorders may be used, although with variable success.</p>
</sec>
</div>
</front>
<back>
<div1 type="bibliography">
<listBibl>
<biblStruct>
<analytic>
<author>
<name sortKey="Curtis, Arj" uniqKey="Curtis A">ARJ Curtis</name>
</author>
<author>
<name sortKey="Fey, C" uniqKey="Fey C">C Fey</name>
</author>
<author>
<name sortKey="Morris, Cm" uniqKey="Morris C">CM Morris</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Chinnery, Pf" uniqKey="Chinnery P">PF Chinnery</name>
</author>
<author>
<name sortKey="Crompton, De" uniqKey="Crompton D">DE Crompton</name>
</author>
<author>
<name sortKey="Birchall, D" uniqKey="Birchall D">D Birchall</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Schneider, Sa" uniqKey="Schneider S">SA Schneider</name>
</author>
<author>
<name sortKey="Dusek, P" uniqKey="Dusek P">P Dusek</name>
</author>
<author>
<name sortKey="Hardy, J" uniqKey="Hardy J">J Hardy</name>
</author>
<author>
<name sortKey="Westenberger, A" uniqKey="Westenberger A">A Westenberger</name>
</author>
<author>
<name sortKey="Jankovic, J" uniqKey="Jankovic J">J Jankovic</name>
</author>
<author>
<name sortKey="Bhatia, Kp" uniqKey="Bhatia K">KP Bhatia</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Dusek, P" uniqKey="Dusek P">P Dusek</name>
</author>
<author>
<name sortKey="Jankovic, J" uniqKey="Jankovic J">J Jankovic</name>
</author>
<author>
<name sortKey="Le, W" uniqKey="Le W">W Le</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Crichton, Rr" uniqKey="Crichton R">RR Crichton</name>
</author>
<author>
<name sortKey="Dexter, Dt" uniqKey="Dexter D">DT Dexter</name>
</author>
<author>
<name sortKey="Ward, Rj" uniqKey="Ward R">RJ Ward</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Ward, Rj" uniqKey="Ward R">RJ Ward</name>
</author>
<author>
<name sortKey="Zucca, Fa" uniqKey="Zucca F">FA Zucca</name>
</author>
<author>
<name sortKey="Duyn, Jh" uniqKey="Duyn J">JH Duyn</name>
</author>
<author>
<name sortKey="Crichton, Rr" uniqKey="Crichton R">RR Crichton</name>
</author>
<author>
<name sortKey="Zecca, L" uniqKey="Zecca L">L Zecca</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Levi, S" uniqKey="Levi S">S Levi</name>
</author>
<author>
<name sortKey="Cozzi, A" uniqKey="Cozzi A">A Cozzi</name>
</author>
<author>
<name sortKey="Arosio, P" uniqKey="Arosio P">P Arosio</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Ramos, P" uniqKey="Ramos P">P Ramos</name>
</author>
<author>
<name sortKey="Santos, A" uniqKey="Santos A">A Santos</name>
</author>
<author>
<name sortKey="Pinto, Nr" uniqKey="Pinto N">NR Pinto</name>
</author>
<author>
<name sortKey="Mendes, R" uniqKey="Mendes R">R Mendes</name>
</author>
<author>
<name sortKey="Magalhaes, T" uniqKey="Magalhaes T">T Magalhães</name>
</author>
<author>
<name sortKey="Almeida, A" uniqKey="Almeida A">A Almeida</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Leitner, Df" uniqKey="Leitner D">DF Leitner</name>
</author>
<author>
<name sortKey="Connor, Jr" uniqKey="Connor J">JR Connor</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Dringen, R" uniqKey="Dringen R">R Dringen</name>
</author>
<author>
<name sortKey="Bishop, Gm" uniqKey="Bishop G">GM Bishop</name>
</author>
<author>
<name sortKey="Koeppe, M" uniqKey="Koeppe M">M Koeppe</name>
</author>
<author>
<name sortKey="Dang, Tn" uniqKey="Dang T">TN Dang</name>
</author>
<author>
<name sortKey="Robinson, Sr" uniqKey="Robinson S">SR Robinson</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Levi, S" uniqKey="Levi S">S Levi</name>
</author>
<author>
<name sortKey="Rovida, E" uniqKey="Rovida E">E Rovida</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Levi, S" uniqKey="Levi S">S Levi</name>
</author>
<author>
<name sortKey="Finazzi, D" uniqKey="Finazzi D">D Finazzi</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Vidal, R" uniqKey="Vidal R">R Vidal</name>
</author>
<author>
<name sortKey="Ghetti, B" uniqKey="Ghetti B">B Ghetti</name>
</author>
<author>
<name sortKey="Takao, M" uniqKey="Takao M">M Takao</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Storti, E" uniqKey="Storti E">E Storti</name>
</author>
<author>
<name sortKey="Cortese, F" uniqKey="Cortese F">F Cortese</name>
</author>
<author>
<name sortKey="Di Fabio, R" uniqKey="Di Fabio R">R Di Fabio</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Chinnery, Pf" uniqKey="Chinnery P">PF Chinnery</name>
</author>
<author>
<name sortKey="Curtis, Arj" uniqKey="Curtis A">ARJ Curtis</name>
</author>
<author>
<name sortKey="Fey, C" uniqKey="Fey C">C Fey</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Mancuso, M" uniqKey="Mancuso M">M Mancuso</name>
</author>
<author>
<name sortKey="Davidzon, G" uniqKey="Davidzon G">G Davidzon</name>
</author>
<author>
<name sortKey="Kurlan, Rm" uniqKey="Kurlan R">RM Kurlan</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Maciel, P" uniqKey="Maciel P">P Maciel</name>
</author>
<author>
<name sortKey="Cruz, Vt" uniqKey="Cruz V">VT Cruz</name>
</author>
<author>
<name sortKey="Constante, M" uniqKey="Constante M">M Constante</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Ohta, E" uniqKey="Ohta E">E Ohta</name>
</author>
<author>
<name sortKey="Takiyama, Y" uniqKey="Takiyama Y">Y Takiyama</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Kubota, A" uniqKey="Kubota A">A Kubota</name>
</author>
<author>
<name sortKey="Hida, A" uniqKey="Hida A">A Hida</name>
</author>
<author>
<name sortKey="Ichikawa, Y" uniqKey="Ichikawa Y">Y Ichikawa</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Devos, D" uniqKey="Devos D">D Devos</name>
</author>
<author>
<name sortKey="Tchofo, Pj" uniqKey="Tchofo P">PJ Tchofo</name>
</author>
<author>
<name sortKey="Vuillaume, I" uniqKey="Vuillaume I">I Vuillaume</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Moutton, S" uniqKey="Moutton S">S Moutton</name>
</author>
<author>
<name sortKey="Fergelot, P" uniqKey="Fergelot P">P Fergelot</name>
</author>
<author>
<name sortKey="Trocello, Jm" uniqKey="Trocello J">JM Trocello</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Nishida, K" uniqKey="Nishida K">K Nishida</name>
</author>
<author>
<name sortKey="Garringer, Hj" uniqKey="Garringer H">HJ Garringer</name>
</author>
<author>
<name sortKey="Futamura, N" uniqKey="Futamura N">N Futamura</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Wills, Aj" uniqKey="Wills A">AJ Wills</name>
</author>
<author>
<name sortKey="Sawle, Gv" uniqKey="Sawle G">GV Sawle</name>
</author>
<author>
<name sortKey="Guilbert, Pr" uniqKey="Guilbert P">PR Guilbert</name>
</author>
<author>
<name sortKey="Curtis, Arj" uniqKey="Curtis A">ARJ Curtis</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Crompton, De" uniqKey="Crompton D">DE Crompton</name>
</author>
<author>
<name sortKey="Chinnery, Pf" uniqKey="Chinnery P">PF Chinnery</name>
</author>
<author>
<name sortKey="Bates, D" uniqKey="Bates D">D Bates</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Caparros Lefebvre, D" uniqKey="Caparros Lefebvre D">D Caparros-Lefebvre</name>
</author>
<author>
<name sortKey="Destee, A" uniqKey="Destee A">A Destee</name>
</author>
<author>
<name sortKey="Petit, H" uniqKey="Petit H">H Petit</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Ondo, Wg" uniqKey="Ondo W">WG Ondo</name>
</author>
<author>
<name sortKey="Adam, Or" uniqKey="Adam O">OR Adam</name>
</author>
<author>
<name sortKey="Jankovic, J" uniqKey="Jankovic J">J Jankovic</name>
</author>
<author>
<name sortKey="Chinnery, Pf" uniqKey="Chinnery P">PF Chinnery</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Lehn, A" uniqKey="Lehn A">A Lehn</name>
</author>
<author>
<name sortKey="Boyle, R" uniqKey="Boyle R">R Boyle</name>
</author>
<author>
<name sortKey="Brown, H" uniqKey="Brown H">H Brown</name>
</author>
<author>
<name sortKey="Airey, C" uniqKey="Airey C">C Airey</name>
</author>
<author>
<name sortKey="Mellick, G" uniqKey="Mellick G">G Mellick</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Keogh, Mj" uniqKey="Keogh M">MJ Keogh</name>
</author>
<author>
<name sortKey="Aribisala, Bs" uniqKey="Aribisala B">BS Aribisala</name>
</author>
<author>
<name sortKey="He, J" uniqKey="He J">J He</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Mcneill, A" uniqKey="Mcneill A">A McNeill</name>
</author>
<author>
<name sortKey="Gorman, G" uniqKey="Gorman G">G Gorman</name>
</author>
<author>
<name sortKey="Khan, A" uniqKey="Khan A">A Khan</name>
</author>
<author>
<name sortKey="Horvath, R" uniqKey="Horvath R">R Horvath</name>
</author>
<author>
<name sortKey="Blamire, Am" uniqKey="Blamire A">AM Blamire</name>
</author>
<author>
<name sortKey="Chinnery, Pf" uniqKey="Chinnery P">PF Chinnery</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Batla, A" uniqKey="Batla A">A Batla</name>
</author>
<author>
<name sortKey="Adams, Me" uniqKey="Adams M">ME Adams</name>
</author>
<author>
<name sortKey="Erro, R" uniqKey="Erro R">R Erro</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Ory Magne, F" uniqKey="Ory Magne F">F Ory-Magne</name>
</author>
<author>
<name sortKey="Brefel Courbon, C" uniqKey="Brefel Courbon C">C Brefel-Courbon</name>
</author>
<author>
<name sortKey="Payoux, P" uniqKey="Payoux P">P Payoux</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Ohta, E" uniqKey="Ohta E">E Ohta</name>
</author>
<author>
<name sortKey="Nagasaka, T" uniqKey="Nagasaka T">T Nagasaka</name>
</author>
<author>
<name sortKey="Shindo, K" uniqKey="Shindo K">K Shindo</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Crompton, De" uniqKey="Crompton D">DE Crompton</name>
</author>
<author>
<name sortKey="Chinnery, Pf" uniqKey="Chinnery P">PF Chinnery</name>
</author>
<author>
<name sortKey="Fey, C" uniqKey="Fey C">C Fey</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Keogh, Mj" uniqKey="Keogh M">MJ Keogh</name>
</author>
<author>
<name sortKey="Singh, B" uniqKey="Singh B">B Singh</name>
</author>
<author>
<name sortKey="Chinnery, Pf" uniqKey="Chinnery P">PF Chinnery</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Mir, P" uniqKey="Mir P">P Mir</name>
</author>
<author>
<name sortKey="Edwards, Mj" uniqKey="Edwards M">MJ Edwards</name>
</author>
<author>
<name sortKey="Curtis, Arj" uniqKey="Curtis A">ARJ Curtis</name>
</author>
<author>
<name sortKey="Bhatia, Kp" uniqKey="Bhatia K">KP Bhatia</name>
</author>
<author>
<name sortKey="Quinn, Np" uniqKey="Quinn N">NP Quinn</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Mcneill, A" uniqKey="Mcneill A">A McNeill</name>
</author>
<author>
<name sortKey="Birchall, D" uniqKey="Birchall D">D Birchall</name>
</author>
<author>
<name sortKey="Hayflick, Sj" uniqKey="Hayflick S">SJ Hayflick</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Taly, Ab" uniqKey="Taly A">AB Taly</name>
</author>
<author>
<name sortKey="Meenakshi Sundaram, S" uniqKey="Meenakshi Sundaram S">S Meenakshi-Sundaram</name>
</author>
<author>
<name sortKey="Sinha, S" uniqKey="Sinha S">S Sinha</name>
</author>
<author>
<name sortKey="Swamy, Hs" uniqKey="Swamy H">HS Swamy</name>
</author>
<author>
<name sortKey="Arunodaya, Gr" uniqKey="Arunodaya G">GR Arunodaya</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Das, Sk" uniqKey="Das S">SK Das</name>
</author>
<author>
<name sortKey="Ray, K" uniqKey="Ray K">K Ray</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Walker, Rh" uniqKey="Walker R">RH Walker</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Martino, D" uniqKey="Martino D">D Martino</name>
</author>
<author>
<name sortKey="Stamelou, M" uniqKey="Stamelou M">M Stamelou</name>
</author>
<author>
<name sortKey="Bhatia, Kp" uniqKey="Bhatia K">KP Bhatia</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Walker, Rh" uniqKey="Walker R">RH Walker</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Balint, B" uniqKey="Balint B">B Balint</name>
</author>
<author>
<name sortKey="Bhatia, Kp" uniqKey="Bhatia K">KP Bhatia</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Houlden, H" uniqKey="Houlden H">H Houlden</name>
</author>
<author>
<name sortKey="Singleton, Ab" uniqKey="Singleton A">AB Singleton</name>
</author>
</analytic>
</biblStruct>
</listBibl>
</div1>
</back>
</TEI>
<pmc article-type="review-article">
<pmc-dir>properties open_access</pmc-dir>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Tremor Other Hyperkinet Mov (N Y)</journal-id>
<journal-id journal-id-type="iso-abbrev">Tremor Other Hyperkinet Mov (N Y)</journal-id>
<journal-id journal-id-type="publisher-id">TOHM</journal-id>
<journal-title-group>
<journal-title>Tremor and Other Hyperkinetic Movements</journal-title>
</journal-title-group>
<issn pub-type="epub">2160-8288</issn>
<publisher>
<publisher-name>Columbia University Libraries/Information Services</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">27022507</article-id>
<article-id pub-id-type="pmc">4795517</article-id>
<article-id pub-id-type="doi">10.7916/D8KK9BHF</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Reviews</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Neuroferritinopathy: Pathophysiology, Presentation, Differential Diagnoses and Management</article-title>
<alt-title alt-title-type="running-head">Neuroferritinopathy</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Kumar</surname>
<given-names>Niraj</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Rizek</surname>
<given-names>Philippe</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Jog</surname>
<given-names>Mandar</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="corresp" rid="cor1">
<sup>*</sup>
</xref>
</contrib>
</contrib-group>
<aff id="aff1">
<label>1</label>
<addr-line>Department of Clinical Neurological Sciences, Western University, London, ON, Canada</addr-line>
</aff>
<contrib-group>
<contrib contrib-type="editor">
<name>
<surname>Walker</surname>
<given-names>Ruth</given-names>
</name>
</contrib>
</contrib-group>
<aff id="edit1">
<addr-line>James J. Peters Veterans Affairs Medical Center, Mount Sinai School of Medicine, USA</addr-line>
</aff>
<author-notes>
<corresp id="cor1">*To whom correspondence should be addressed. E-mail:
<email>mandar.jog@lhsc.on.ca</email>
</corresp>
</author-notes>
<pub-date pub-type="collection">
<year>2016</year>
</pub-date>
<pub-date pub-type="epub">
<day>08</day>
<month>3</month>
<year>2016</year>
</pub-date>
<volume>6</volume>
<elocation-id>355</elocation-id>
<history>
<date date-type="received">
<day>8</day>
<month>10</month>
<year>2015</year>
</date>
<date date-type="accepted">
<day>14</day>
<month>1</month>
<year>2016</year>
</date>
</history>
<permissions>
<copyright-year>2016</copyright-year>
<copyright-holder>Kumar et al</copyright-holder>
<license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/">
<license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution–Noncommerical–No Derivatives License, which permits the user to copy, distribute, and transmit the work provided that the original author and source are credited; that no commercial use is made of the work; and that the work is not altered or transformed.</license-p>
</license>
</permissions>
<abstract>
<sec>
<title>Background</title>
<p>Neuroferritinopathy (NF) is a rare autosomal dominant disease caused by mutations in the ferritin light chain 1 (
<italic>FTL1</italic>
) gene leading to abnormal excessive iron accumulation in the brain, predominantly in the basal ganglia.</p>
</sec>
<sec>
<title>Methods</title>
<p>A literature search was performed on Pubmed, for English-language articles, utilizing the terms iron metabolism, neurodegeneration with brain iron accumulation, and NF. The relevant articles were reviewed with a focus on the pathophysiology, clinical presentation, differential diagnoses, and management of NF.</p>
</sec>
<sec>
<title>Results</title>
<p>There have been nine reported mutations worldwide in the
<italic>FTL1</italic>
gene in 90 patients, the most common mutation being 460InsA. Chorea and dystonia are the most common presenting symptoms in NF. There are specific features, which appear to depend upon the genetic mutation. We discuss the occurrence of specific mutations in various regions along with their associated presenting phenomenology. We have compared and contrasted the commonly occurring syndromes in the differential diagnosis of NF to guide the clinician.</p>
</sec>
<sec>
<title>Discussion</title>
<p>NF must be considered in patients presenting clinically as a progressive movement disorder with variable phenotype and imaging evidence of iron deposition within the brain, decreased serum ferritin, and negative genetic testing for other more common movement disorders such as Huntington’s disease. In the absence of a disease-specific treatment, symptomatic drug therapy for specific movement disorders may be used, although with variable success.</p>
</sec>
</abstract>
<kwd-group>
<kwd>Neuroferritinopathy</kwd>
<kwd>
<italic>FTL1</italic>
gene</kwd>
<kwd>chorea</kwd>
<kwd>dystonia</kwd>
<kwd>neurodegeneration with brain iron accumulation</kwd>
<kwd>Huntington’s disease</kwd>
<kwd>hereditary ferritinopathy</kwd>
</kwd-group>
<counts>
<page-count count="10"></page-count>
</counts>
</article-meta>
</front>
<body>
<sec id="s1">
<title>Introduction</title>
<p>Neuroferritinopathy (NF) is an autosomal dominant, late-onset basal ganglia disorder resulting from mutations in the gene for ferritin light chain 1 (
<italic>FTL1</italic>
) on chromosome 19q13.
<xref rid="b01" ref-type="bibr">1</xref>
,
<xref rid="b02" ref-type="bibr">2</xref>
The pathogenic mutations in the
<italic>FTL1</italic>
gene cause pathological iron deposition and ferritin inclusions in various brain regions, respecting the pattern observed in normal aging.
<xref rid="b01" ref-type="bibr">1</xref>
NF belongs to the group of disorders collectively known as neurodegeneration with brain iron accumulation (NBIA). The NBIAs present as a progressive extrapyramidal syndrome with abnormally increased iron deposition in the brain, particularly affecting the basal ganglia.
<xref rid="b03" ref-type="bibr">3</xref>
Pantothenate kinase-associated neurodegeneration (PKAN) and
<italic>PLA2G6</italic>
-associated neurodegeneration are the two most common disorders in this group. NF is one of only two disorders in this expanding group of NBIAs caused by a mutation in genes directly involved in iron metabolism; the other being aceruloplasminemia.
<xref rid="b04" ref-type="bibr">4</xref>
It is the only autosomal dominant NBIA disorder, and patients present late in adulthood with combinations of movement disorders.
<xref rid="b02" ref-type="bibr">2</xref>
To date, 90 cases of NF have been identified with nine causative mutations. On the basis of recent advances in our knowledge about NF, we review the various aspects of NF, namely the pathophysiology, genetics, clinical manifestations, differential diagnosis, treatment options, and prognosis.</p>
</sec>
<sec id="s2">
<title>Pathophysiology</title>
<p>The brain requires iron for many of its essential activities including transport of oxygen, energy generation, development of oligodendrocytes, myelin synthesis, production of neurotransmitters (dopamine, serotonin, and norepinephrine), and metabolism of nitric oxide.
<xref rid="b05" ref-type="bibr">5</xref>
,
<xref rid="b06" ref-type="bibr">6</xref>
The brain contains about 30–40 mg of iron, which forms less than 1% of the total iron in our body.
<xref rid="b07" ref-type="bibr">7</xref>
Disturbances in the homeostatic mechanisms of iron metabolism cause oxidative stress and cellular damage.
<xref rid="b06" ref-type="bibr">6</xref>
Iron content in the brain increases with age, but it is still unclear whether its accumulation in neurodegenerative disorders is a primary or a secondary phenomenon.
<xref rid="b03" ref-type="bibr">3</xref>
,
<xref rid="b04" ref-type="bibr">4</xref>
The distribution of iron in the brain is not homogeneous. The basal ganglia (caudate, putamen, and globus pallidus) have the highest iron concentrations, while the cortex, brainstem, and cerebellum have relatively lower concentrations.
<xref rid="b06" ref-type="bibr">6</xref>
,
<xref rid="b08" ref-type="bibr">8</xref>
Iron is mainly stored intracellularly in the ferritin complex; however, in the substantia nigra and locus ceruleus, neuromelanin is the major iron storage molecule.
<xref rid="b04" ref-type="bibr">4</xref>
</p>
<p>To get into the brain, iron needs to cross the blood–brain barrier and blood–cerebrospinal fluid (CSF) barrier. Iron is transported by transferrin (Tf), which binds to transferrin receptors (TfR) on the cell surface.
<xref rid="b09" ref-type="bibr">9</xref>
Of the two TfRs (TfR1 and TfR2), TfR1 plays the primary role in iron transfer.
<xref rid="b09" ref-type="bibr">9</xref>
The Tf–TfR system is mainly responsible for exporting iron from the vascular lumen into the vascular endothelial cells. Iron is exported out of the basolateral membrane through some unknown transporters, which may involve ferroportin.
<xref rid="b06" ref-type="bibr">6</xref>
Extracellular iron then enters the astrocytes as low molecular weight complexes (e.g. citrate, adenosine triphosphate, ascorbate) or it may enter the neurons via the Tf–TfR pathways (
<xref ref-type="fig" rid="f01">Figure 1</xref>
).
<xref rid="b09" ref-type="bibr">9</xref>
Iron can be stored as ferritin in astrocytes and released through ferroportin and ceruloplasmin, the ferroxidase that oxidizes ferrous iron.
<xref rid="b10" ref-type="bibr">10</xref>
Astrocytes are ideally positioned to take up iron from the circulation and disperse it among other central nervous system cells.
<xref rid="b10" ref-type="bibr">10</xref>
</p>
<fig id="f01" orientation="portrait" position="float">
<label>Figure 1</label>
<caption>
<title>Cellular Iron Metabolism in the Central Nervous System and Abnormalities in Neuroferritinopathy. Adapted from Dringen et al.
<xref rid="b10" ref-type="bibr">10</xref>
, Schneider et al.
<xref rid="b03" ref-type="bibr">3</xref>
and Levi and Finazzi.
<xref rid="b12" ref-type="bibr">12</xref>
Transferrin (Tf)-bound ferric iron (Fe
<sup>3+</sup>
) enters the cell (astrocyte) through adenosine triphosphate (ATP)-dependent transferrin receptor (TfR)-mediated endocytosis, and ferrous iron (Fe
<sup>2+</sup>
) via a divalent metal transporter 1 (DMT1). STEAP 3, a ferrireductase, converts Fe
<sup>3+</sup>
to Fe
<sup>2+</sup>
. Excess iron is stored in ferritin as Fe
<sup>3+</sup>
. Fe
<sup>2+</sup>
is exported out via ferroportin (FP), where it is oxidized by ceruloplasmin (CP) to Fe
<sup>3+</sup>
and is available for other central nervous system cells, i.e., neurons and oligodendrocytes. The solid arrows show the normal iron metabolic pathways and the dotted arrows depict the pathogenic mechanisms in neuroferritinopathy (NF). The
<italic>FTL1</italic>
gene mutation reduces the effectiveness of iron incorporation in ferritin and causes faster ferritin degradation. In turn, the increase in cytosolic iron induces upregulation of the abnormal ferritin. This stimulates production of reactive oxygen species (ROS) and oxidative damage leading to proteasome impairment and cell death. H, Heavy Subunit; L, Light Subunit.</title>
</caption>
<graphic xlink:href="tre-06-355-7522-1-g001"></graphic>
</fig>
<p>Ferritin, the major iron storage protein, has a spherical shell with an internal cavity that can store 4,500 iron atoms.
<xref rid="b11" ref-type="bibr">11</xref>
It is composed of two subunit types, heavy (H) and light (L), which are encoded by genes on chromosomes 11 and 19, respectively.
<xref rid="b07" ref-type="bibr">7</xref>
,
<xref rid="b11" ref-type="bibr">11</xref>
Both H and L chains are essential as the heteropolymers assimilate iron more effectively than homopolymers.
<xref rid="b12" ref-type="bibr">12</xref>
In NF, the mutations produce a lengthening of the C terminus of the L chain that impairs its normal interaction with the heavy chain, thereby impairing the iron-binding capacity of ferritin.
<xref rid="b11" ref-type="bibr">11</xref>
,
<xref rid="b13" ref-type="bibr">13</xref>
This results in accumulation of ferrous or free iron (Fe
<sup>2+</sup>
), which causes damage by producing free radicals, and a compensatory upregulation of ferritin production (
<xref ref-type="fig" rid="f01">Figure 1</xref>
).
<xref rid="b01" ref-type="bibr">1</xref>
,
<xref rid="b13" ref-type="bibr">13</xref>
Oxidative stress leads to neurodegeneration.
<xref rid="b12" ref-type="bibr">12</xref>
Mitochondrial dysfunction may also contribute to the cellular dysfunction in NF probably by affecting neuronal intramitochondrial iron handling.
<xref rid="b02" ref-type="bibr">2</xref>
,
<xref rid="b14" ref-type="bibr">14</xref>
<xref rid="b16" ref-type="bibr">16</xref>
</p>
<p>Curtis et al. were the first group to report NF cases in a large north England family from the Cumbria region who had dominantly inherited, adult-onset basal ganglia disease.
<xref rid="b01" ref-type="bibr">1</xref>
They found a mutation of an adenine insertion at position 460–461 in exon 4 of the
<italic>FTL1</italic>
gene, which caused a frameshift and led to alterations at the C terminus of the gene product. The number of reported cases and mutations in NF are gradually increasing, thus underlining the fact that NF is neither purely confined to the population of north England nor confined to a common founder, as was once thought (
<xref ref-type="table" rid="t01">Table 1</xref>
).
<xref rid="b02" ref-type="bibr">2</xref>
,
<xref rid="b13" ref-type="bibr">13</xref>
,
<xref rid="b14" ref-type="bibr">14</xref>
,
<xref rid="b16" ref-type="bibr">16</xref>
<xref rid="b22" ref-type="bibr">22</xref>
Most
<italic>FTL1</italic>
mutations are located on exon 4, commonly resulting in a frameshift, suggesting that this part of the gene is particularly vulnerable to mutation.
<xref rid="b11" ref-type="bibr">11</xref>
</p>
<p>
<table-wrap id="t01" orientation="portrait" position="float">
<label>Table 1</label>
<caption>
<title>Summary of the Genetics, and Clinical and Radiological Features of All Reported Neuroferritinopathy Cases</title>
</caption>
<table frame="hsides" rules="groups" width="95%">
<thead style="border-bottom: thin solid; border-top: thin solid; border-color: #000000">
<tr>
<th align="left" rowspan="2" colspan="1">
<italic>FTL1</italic>
Mutation (In Order of Identification)</th>
<th align="left" rowspan="2" colspan="1">Place of Origin (Study)</th>
<th align="left" rowspan="2" colspan="1">Number of Cases (M:F)</th>
<th align="left" rowspan="2" colspan="1">Mean Onset Age (Years)</th>
<th align="left" colspan="7" rowspan="1">Movement Disorders</th>
<th align="left" rowspan="2" colspan="1">Co and Np</th>
<th align="left" rowspan="2" colspan="1">MRI Brain</th>
<th align="left" rowspan="2" colspan="1">Serum Ferritin</th>
</tr>
<tr>
<th align="left" rowspan="1" colspan="1">D</th>
<th align="left" rowspan="1" colspan="1">Ch</th>
<th align="left" rowspan="1" colspan="1">Pk</th>
<th align="left" rowspan="1" colspan="1">Tr</th>
<th align="left" rowspan="1" colspan="1">At</th>
<th align="left" rowspan="1" colspan="1">T/S</th>
<th align="left" rowspan="1" colspan="1">O</th>
</tr>
</thead>
<tbody style="border-color: #000000; border-bottom: thin solid">
<tr>
<td valign="top" rowspan="1" align="center" colspan="1">460InsA</td>
<td valign="top" align="left" rowspan="1" colspan="1">UK Chinnery et al.
<xref rid="b02" ref-type="bibr">2</xref>
It includes cases from other studies
<xref rid="b01" ref-type="bibr">1</xref>
,
<xref rid="b15" ref-type="bibr">15</xref>
,
<xref rid="b23" ref-type="bibr">23</xref>
<xref rid="b25" ref-type="bibr">25</xref>
</td>
<td valign="top" align="left" rowspan="1" colspan="1">41 (20:21), incl. 1 asymp.</td>
<td valign="top" align="left" rowspan="1" colspan="1">39.4</td>
<td valign="top" align="left" rowspan="1" colspan="1">+</td>
<td valign="top" align="left" rowspan="1" colspan="1">+</td>
<td valign="top" align="left" rowspan="1" colspan="1">+</td>
<td valign="top" align="left" rowspan="1" colspan="1">+</td>
<td valign="top" align="left" rowspan="1" colspan="1"></td>
<td valign="top" align="left" rowspan="1" colspan="1"></td>
<td valign="top" align="left" rowspan="1" colspan="1">+</td>
<td valign="top" align="left" rowspan="1" colspan="1">+</td>
<td valign="top" align="left" rowspan="1" colspan="1">
<list list-type="bullet">
<list-item>
<p>T2 decr. in DN, RN, SN, P, GP, Th, CN</p>
</list-item>
<list-item>
<p>Incr. with surrounding decr. on T2W in P, GP, Th
<xref rid="b23" ref-type="bibr">23</xref>
</p>
</list-item>
</list>
</td>
<td valign="top" align="left" rowspan="1" colspan="1">Decr.</td>
</tr>
<tr>
<td valign="top" align="left" rowspan="1" colspan="1"></td>
<td valign="top" align="left" rowspan="1" colspan="1">USA Ondo et al.
<xref rid="b26" ref-type="bibr">26</xref>
</td>
<td valign="top" align="left" rowspan="1" colspan="1">2 (2:0)</td>
<td valign="top" align="left" rowspan="1" colspan="1">48.5</td>
<td valign="top" align="left" rowspan="1" colspan="1"></td>
<td valign="top" align="left" rowspan="1" colspan="1">+</td>
<td valign="top" align="left" rowspan="1" colspan="1"></td>
<td valign="top" align="left" rowspan="1" colspan="1"></td>
<td valign="top" align="left" rowspan="1" colspan="1">+</td>
<td valign="top" align="left" rowspan="1" colspan="1">+</td>
<td valign="top" align="left" rowspan="1" colspan="1">+</td>
<td valign="top" align="left" rowspan="1" colspan="1"></td>
<td valign="top" align="left" rowspan="1" colspan="1">
<list list-type="bullet">
<list-item>
<p>T2 and flair lesions in the GP and cerebellum</p>
</list-item>
</list>
</td>
<td valign="top" align="left" rowspan="1" colspan="1">Decr.</td>
</tr>
<tr>
<td valign="top" align="left" rowspan="1" colspan="1"></td>
<td valign="top" align="left" rowspan="1" colspan="1">Australia (British ancestry) Lehn et al.
<xref rid="b27" ref-type="bibr">27</xref>
</td>
<td valign="top" align="left" rowspan="1" colspan="1">5 (5:0)</td>
<td valign="top" align="left" rowspan="1" colspan="1">47</td>
<td valign="top" align="left" rowspan="1" colspan="1">+</td>
<td valign="top" align="left" rowspan="1" colspan="1">+</td>
<td valign="top" align="left" rowspan="1" colspan="1">+</td>
<td valign="top" align="left" rowspan="1" colspan="1">+</td>
<td valign="top" align="left" rowspan="1" colspan="1"></td>
<td valign="top" align="left" rowspan="1" colspan="1">+</td>
<td valign="top" align="left" rowspan="1" colspan="1">+</td>
<td valign="top" align="left" rowspan="1" colspan="1">+</td>
<td valign="top" align="left" rowspan="1" colspan="1">
<list list-type="bullet">
<list-item>
<p>SWI showed iron deposition in RN, SN, GP and motor cortex</p>
</list-item>
</list>
</td>
<td valign="top" align="left" rowspan="1" colspan="1">Decr.</td>
</tr>
<tr>
<td valign="top" align="left" rowspan="1" colspan="1"></td>
<td valign="top" align="left" rowspan="1" colspan="1">UK Keogh et al.
<xref rid="b28" ref-type="bibr">28</xref>
McNeill et al.
<xref rid="b29" ref-type="bibr">29</xref>
</td>
<td valign="top" align="left" rowspan="1" colspan="1">10 (5:5)</td>
<td valign="top" align="left" rowspan="1" colspan="1">48.5</td>
<td valign="top" align="left" rowspan="1" colspan="1">+</td>
<td valign="top" align="left" rowspan="1" colspan="1">+</td>
<td valign="top" align="left" rowspan="1" colspan="1">+</td>
<td valign="top" align="left" rowspan="1" colspan="1"></td>
<td valign="top" align="left" rowspan="1" colspan="1"></td>
<td valign="top" align="left" rowspan="1" colspan="1"></td>
<td valign="top" align="left" rowspan="1" colspan="1"></td>
<td valign="top" align="left" rowspan="1" colspan="1"></td>
<td valign="top" align="left" rowspan="1" colspan="1">
<list list-type="bullet">
<list-item>
<p>BG cavitation</p>
</list-item>
<list-item>
<p>T2 decr. in Th
<xref rid="b29" ref-type="bibr">29</xref>
</p>
</list-item>
<list-item>
<p>T1 incr. in CN and decr. in GP</p>
</list-item>
<list-item>
<p>Cerebellar atrophy</p>
</list-item>
<list-item>
<p>Lingual gyrus involvement
<xref rid="b28" ref-type="bibr">28</xref>
</p>
</list-item>
</list>
</td>
<td valign="top" align="left" rowspan="1" colspan="1">Decr. (
<italic>n</italic>
 = 8) & low normal (
<italic>n</italic>
 = 2)</td>
</tr>
<tr>
<td valign="top" align="left" rowspan="1" colspan="1"></td>
<td valign="top" align="left" rowspan="1" colspan="1">UK Batla et al.
<xref rid="b30" ref-type="bibr">30</xref>
</td>
<td valign="top" align="left" rowspan="1" colspan="1">3 (1:2)</td>
<td valign="top" align="left" rowspan="1" colspan="1">50.7</td>
<td valign="top" align="left" rowspan="1" colspan="1">+</td>
<td valign="top" align="left" rowspan="1" colspan="1"></td>
<td valign="top" align="left" rowspan="1" colspan="1">+</td>
<td valign="top" align="left" rowspan="1" colspan="1"></td>
<td valign="top" align="left" rowspan="1" colspan="1">+</td>
<td valign="top" align="left" rowspan="1" colspan="1"></td>
<td valign="top" align="left" rowspan="1" colspan="1">+</td>
<td valign="top" align="left" rowspan="1" colspan="1"></td>
<td valign="top" align="left" rowspan="1" colspan="1">
<list list-type="bullet">
<list-item>
<p>SWI showed pencil lining in cerebral and cerebellar cortex</p>
</list-item>
</list>
</td>
<td valign="top" align="left" rowspan="1" colspan="1">Decr.</td>
</tr>
<tr>
<td valign="top" align="left" rowspan="1" colspan="1">498InsTC</td>
<td valign="top" align="left" rowspan="1" colspan="1">France Vidal et al.
<xref rid="b13" ref-type="bibr">13</xref>
and Ory-Magne et al.
<xref rid="b31" ref-type="bibr">31</xref>
</td>
<td valign="top" align="left" rowspan="1" colspan="1">11 (7:4)</td>
<td valign="top" align="left" rowspan="1" colspan="1">36.8</td>
<td valign="top" align="left" rowspan="1" colspan="1">+</td>
<td valign="top" align="left" rowspan="1" colspan="1">+</td>
<td valign="top" align="left" rowspan="1" colspan="1">+</td>
<td valign="top" align="left" rowspan="1" colspan="1">+</td>
<td valign="top" align="left" rowspan="1" colspan="1">+</td>
<td valign="top" align="left" rowspan="1" colspan="1"></td>
<td valign="top" align="left" rowspan="1" colspan="1">+</td>
<td valign="top" align="left" rowspan="1" colspan="1">+</td>
<td valign="top" align="left" rowspan="1" colspan="1">
<list list-type="bullet">
<list-item>
<p>T2 decr. and T1 incr. in BG</p>
</list-item>
</list>
</td>
<td valign="top" align="left" rowspan="1" colspan="1">Decr. (
<italic>n</italic>
 = 2)</td>
</tr>
<tr>
<td valign="top" align="left" rowspan="1" colspan="1">474G→A</td>
<td valign="top" align="left" rowspan="1" colspan="1">Portugal Maciel et al.
<xref rid="b17" ref-type="bibr">17</xref>
</td>
<td valign="top" align="left" rowspan="1" colspan="1">3 (2:1); incl. 2 asymp.</td>
<td valign="top" align="left" rowspan="1" colspan="1">13</td>
<td valign="top" align="left" rowspan="1" colspan="1"></td>
<td valign="top" align="left" rowspan="1" colspan="1"></td>
<td valign="top" align="left" rowspan="1" colspan="1">+</td>
<td valign="top" align="left" rowspan="1" colspan="1"></td>
<td valign="top" align="left" rowspan="1" colspan="1">+</td>
<td valign="top" align="left" rowspan="1" colspan="1"></td>
<td valign="top" align="left" rowspan="1" colspan="1"></td>
<td valign="top" align="left" rowspan="1" colspan="1">+</td>
<td valign="top" align="left" rowspan="1" colspan="1">
<list list-type="bullet">
<list-item>
<p>T2 incr. in GP</p>
</list-item>
<list-item>
<p>Cerebral atrophy</p>
</list-item>
</list>
</td>
<td valign="top" align="left" rowspan="1" colspan="1">Decr.</td>
</tr>
<tr>
<td valign="top" align="left" rowspan="1" colspan="1">646InsC</td>
<td valign="top" align="left" rowspan="1" colspan="1">USA (French Canadian and Dutch ancestry) Mancuso et al.
<xref rid="b16" ref-type="bibr">16</xref>
</td>
<td valign="top" align="left" rowspan="1" colspan="1">2 (1:1)</td>
<td valign="top" align="left" rowspan="1" colspan="1">56</td>
<td valign="top" align="left" rowspan="1" colspan="1">+</td>
<td valign="top" align="left" rowspan="1" colspan="1">+</td>
<td valign="top" align="left" rowspan="1" colspan="1"></td>
<td valign="top" align="left" rowspan="1" colspan="1"></td>
<td valign="top" align="left" rowspan="1" colspan="1">+</td>
<td valign="top" align="left" rowspan="1" colspan="1"></td>
<td valign="top" align="left" rowspan="1" colspan="1">+</td>
<td valign="top" align="left" rowspan="1" colspan="1">+</td>
<td valign="top" align="left" rowspan="1" colspan="1">
<list list-type="bullet">
<list-item>
<p>Cerebellar atrophy</p>
</list-item>
<list-item>
<p>T2 incr. in P, GP, CN and SN</p>
</list-item>
</list>
</td>
<td valign="top" align="left" rowspan="1" colspan="1">Low–normal range</td>
</tr>
<tr>
<td valign="top" rowspan="1" align="center" colspan="1">469_484dup16nt</td>
<td valign="top" align="left" rowspan="1" colspan="1">Japan Ohta et al.
<xref rid="b32" ref-type="bibr">32</xref>
</td>
<td valign="top" align="left" rowspan="1" colspan="1">2 (1:1)</td>
<td valign="top" align="left" rowspan="1" colspan="1">Teen-age</td>
<td valign="top" align="left" rowspan="1" colspan="1"></td>
<td valign="top" align="left" rowspan="1" colspan="1"></td>
<td valign="top" align="left" rowspan="1" colspan="1">+</td>
<td valign="top" align="left" rowspan="1" colspan="1">+</td>
<td valign="top" align="left" rowspan="1" colspan="1"></td>
<td valign="top" align="left" rowspan="1" colspan="1"></td>
<td valign="top" align="left" rowspan="1" colspan="1"></td>
<td valign="top" align="left" rowspan="1" colspan="1">+</td>
<td valign="top" align="left" rowspan="1" colspan="1">
<list list-type="bullet">
<list-item>
<p>Cystic changes in GP and striatum</p>
</list-item>
<list-item>
<p>T2 incr. in Th, DN, and SN.</p>
</list-item>
</list>
</td>
<td valign="top" align="left" rowspan="1" colspan="1">Decr.</td>
</tr>
<tr>
<td valign="top" align="left" rowspan="1" colspan="1"></td>
<td valign="top" align="left" rowspan="1" colspan="1">Italy Storti et al.
<xref rid="b14" ref-type="bibr">14</xref>
</td>
<td valign="top" align="left" rowspan="1" colspan="1">1 (1:0)</td>
<td valign="top" align="left" rowspan="1" colspan="1">Late 20s</td>
<td valign="top" align="left" rowspan="1" colspan="1">+</td>
<td valign="top" align="left" rowspan="1" colspan="1"></td>
<td valign="top" align="left" rowspan="1" colspan="1">+</td>
<td valign="top" align="left" rowspan="1" colspan="1">+</td>
<td valign="top" align="left" rowspan="1" colspan="1">+</td>
<td valign="top" align="left" rowspan="1" colspan="1"></td>
<td valign="top" align="left" rowspan="1" colspan="1"></td>
<td valign="top" align="left" rowspan="1" colspan="1">+</td>
<td valign="top" align="left" rowspan="1" colspan="1">
<list list-type="bullet">
<list-item>
<p>Cavitation of bilateral LN</p>
</list-item>
<list-item>
<p>Cortical atrophy</p>
</list-item>
</list>
</td>
<td valign="top" align="left" rowspan="1" colspan="1">Decr.</td>
</tr>
<tr>
<td valign="top" align="left" rowspan="1" colspan="1">458dupA</td>
<td valign="top" align="left" rowspan="1" colspan="1">France Devos et al.
<xref rid="b20" ref-type="bibr">20</xref>
</td>
<td valign="top" align="left" rowspan="1" colspan="1">1 (0:1) + 3 prev. reported (3:0)
<xref rid="b02" ref-type="bibr">2</xref>
</td>
<td valign="top" align="left" rowspan="1" colspan="1">24–44</td>
<td valign="top" align="left" rowspan="1" colspan="1">+</td>
<td valign="top" align="left" rowspan="1" colspan="1"></td>
<td valign="top" align="left" rowspan="1" colspan="1">+</td>
<td valign="top" align="left" rowspan="1" colspan="1"></td>
<td valign="top" align="left" rowspan="1" colspan="1">+</td>
<td valign="top" align="left" rowspan="1" colspan="1"></td>
<td valign="top" align="left" rowspan="1" colspan="1">+</td>
<td valign="top" align="left" rowspan="1" colspan="1">+</td>
<td valign="top" align="left" rowspan="1" colspan="1">
<list list-type="bullet">
<list-item>
<p>Cystic cavitation in BG</p>
</list-item>
<list-item>
<p>Iron deposition in DN, GP, and P</p>
</list-item>
</list>
</td>
<td valign="top" align="left" rowspan="1" colspan="1">Decr.</td>
</tr>
<tr>
<td valign="top" align="left" rowspan="1" colspan="1">641_642 4bp_dup</td>
<td valign="top" align="left" rowspan="1" colspan="1">Japan Kubota et al.
<xref rid="b19" ref-type="bibr">19</xref>
</td>
<td valign="top" align="left" rowspan="1" colspan="1">7 (7:0)</td>
<td valign="top" align="left" rowspan="1" colspan="1">51.8</td>
<td valign="top" align="left" rowspan="1" colspan="1">+</td>
<td valign="top" align="left" rowspan="1" colspan="1">+</td>
<td valign="top" align="left" rowspan="1" colspan="1"></td>
<td valign="top" align="left" rowspan="1" colspan="1">+</td>
<td valign="top" align="left" rowspan="1" colspan="1"></td>
<td valign="top" align="left" rowspan="1" colspan="1"></td>
<td valign="top" align="left" rowspan="1" colspan="1">+</td>
<td valign="top" align="left" rowspan="1" colspan="1">+</td>
<td valign="top" align="left" rowspan="1" colspan="1">
<list list-type="bullet">
<list-item>
<p>T2 incr. with surrounding decr. in GP and P</p>
</list-item>
</list>
</td>
<td valign="top" align="left" rowspan="1" colspan="1">Low–normal range</td>
</tr>
<tr>
<td valign="top" align="left" rowspan="1" colspan="1">468dupT</td>
<td valign="top" align="left" rowspan="1" colspan="1">France Moutton et al.
<xref rid="b21" ref-type="bibr">21</xref>
</td>
<td valign="top" align="left" rowspan="1" colspan="1">1 (1:0)</td>
<td valign="top" align="left" rowspan="1" colspan="1">27</td>
<td valign="top" align="left" rowspan="1" colspan="1">+</td>
<td valign="top" align="left" rowspan="1" colspan="1">+</td>
<td valign="top" align="left" rowspan="1" colspan="1"></td>
<td valign="top" align="left" rowspan="1" colspan="1"></td>
<td valign="top" align="left" rowspan="1" colspan="1"></td>
<td valign="top" align="left" rowspan="1" colspan="1"></td>
<td valign="top" align="left" rowspan="1" colspan="1"></td>
<td valign="top" align="left" rowspan="1" colspan="1">+</td>
<td valign="top" align="left" rowspan="1" colspan="1">
<list list-type="bullet">
<list-item>
<p>BG cavitations</p>
</list-item>
<list-item>
<p>Asymmetrical changes</p>
</list-item>
</list>
</td>
<td valign="top" align="left" rowspan="1" colspan="1">Decr.</td>
</tr>
<tr>
<td valign="top" align="left" rowspan="1" colspan="1">468_483dup16nt</td>
<td valign="top" align="left" rowspan="1" colspan="1">Japan Nishida et al.
<xref rid="b22" ref-type="bibr">22</xref>
</td>
<td valign="top" align="left" rowspan="1" colspan="1">1 (0:1)</td>
<td valign="top" align="left" rowspan="1" colspan="1">42</td>
<td valign="top" align="left" rowspan="1" colspan="1">+</td>
<td valign="top" align="left" rowspan="1" colspan="1"></td>
<td valign="top" align="left" rowspan="1" colspan="1"></td>
<td valign="top" align="left" rowspan="1" colspan="1"></td>
<td valign="top" align="left" rowspan="1" colspan="1">+</td>
<td valign="top" align="left" rowspan="1" colspan="1"></td>
<td valign="top" align="left" rowspan="1" colspan="1">+</td>
<td valign="top" align="left" rowspan="1" colspan="1">+</td>
<td valign="top" align="left" rowspan="1" colspan="1">
<list list-type="bullet">
<list-item>
<p>T2 incr. with surrounding decr. in bilateral posterior GP and P</p>
</list-item>
<list-item>
<p>Mild cerebral and cerebellar atrophy</p>
</list-item>
</list>
</td>
<td valign="top" align="left" rowspan="1" colspan="1">Normal serum ferritin; decr. CSF ferritin</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="TFN01t01">
<p>Abbreviations: A, Adenine Base; Asymp., Asymptomatic; At, Ataxia; BG, Basal Ganglia; C, Cytosine Base; Ch, Chorea; CN, Caudate Nucleus; Co, Cognitive Impairment; CSF, Cerebrospinal Fluid; D, Dystonia; Decr., Decreased; DN, Dentate Nucleus; Dup, Duplication; GP, Globus Pallidus; Incl., Including; Incr., Increased; Ins, Insertion; LN, Lenticular Nuclei; Np, Neuropsychiatric Manifestations; O, Orofacial Dyskinesia; P, Putamen; Pk, Parkinsonism; Prev., Previously; RN, Red Nucleus; SN, Substantia Nigra; SWI, Susceptibility-weighted Imaging; T, Thymine Base; Th, Thalamus; Tr, Tremor; T/S, Tics/Stereotypy.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</p>
</sec>
<sec id="s3">
<title>Clinical features</title>
<p>NF usually presents in the second to fifth decade of life with the mean age of onset being around 40 years.
<xref rid="b01" ref-type="bibr">1</xref>
,
<xref rid="b02" ref-type="bibr">2</xref>
,
<xref rid="b13" ref-type="bibr">13</xref>
,
<xref rid="b15" ref-type="bibr">15</xref>
,
<xref rid="b19" ref-type="bibr">19</xref>
Those with mutations other than 460InsA appear to have an earlier age of onset (
<xref ref-type="table" rid="t01">Table 1</xref>
). The gender of the patients does not affect the age of disease onset or clinical phenotype. Although no predilection was seen for any gender in the largest series,
<xref rid="b02" ref-type="bibr">2</xref>
some series report male predominance.
<xref rid="b19" ref-type="bibr">19</xref>
,
<xref rid="b27" ref-type="bibr">27</xref>
,
<xref rid="b31" ref-type="bibr">31</xref>
It was suggested that females might be less vulnerable to abnormal iron deposition owing to menstruation,
<xref rid="b19" ref-type="bibr">19</xref>
which may explain an asymptomatic 40-year-old female carrier in one of the reports.
<xref rid="b17" ref-type="bibr">17</xref>
The disorder is thought to be fully penetrant by the age of 60.
<xref rid="b02" ref-type="bibr">2</xref>
,
<xref rid="b33" ref-type="bibr">33</xref>
Clinical presentation does not differ with the age of onset. A strong family history is reported in most of the series.
<xref rid="b01" ref-type="bibr">1</xref>
,
<xref rid="b02" ref-type="bibr">2</xref>
,
<xref rid="b13" ref-type="bibr">13</xref>
The disease progresses gradually, first involving basal ganglionic and/or cerebellar functions, and spreads to involve cortical functions in the late stages.
<xref rid="b13" ref-type="bibr">13</xref>
The clinical manifestations vary among NF patients, which may be related to the variability in length of the mutant polypeptide and the resulting dominant negative effect of the modified last alpha-helix domain.
<xref rid="b14" ref-type="bibr">14</xref>
However, there is no known correlation between the length of the mutant polypeptide and the age of onset. Environmental factors like dietary iron intake and other genes influencing iron metabolism may affect the clinical picture.
<xref rid="b21" ref-type="bibr">21</xref>
</p>
<sec id="s3a">
<title>Motor symptoms</title>
<p>NF may present with varied movement disorders. Three of the 90 cases reported to date were asymptomatic,
<xref rid="b01" ref-type="bibr">2</xref>
,
<xref rid="b17" ref-type="bibr">17</xref>
and clinical data were not available for four additional reported NF patients.
<xref rid="b13" ref-type="bibr">13</xref>
,
<xref rid="b31" ref-type="bibr">31</xref>
On analyzing all the symptomatic reported cases of NF (
<italic>n</italic>
 = 83;
<xref ref-type="fig" rid="f02">Figure 2</xref>
), we found chorea (39.7%;
<italic>n</italic>
 = 33) and dystonia (38.5%;
<italic>n</italic>
 = 32) to be the commonest presenting features; however, these were not specific for any particular
<italic>FTL1</italic>
mutation or a geographical region. Parkinsonism (6%;
<italic>n</italic>
 = 5) and tics (1.2%;
<italic>n</italic>
 = 1) as initial presentation were seen in only those patients with 460InsA mutations. Tremor (7.2%;
<italic>n</italic>
 = 6) at the disease onset was seen in patients of French ancestry with 498InsTC, and in Japanese patients with 469_484dup16nt. The 469_484dup16nt mutation is also seen in Italy, presenting with similar clinical features. Cerebellar ataxia (4.8%;
<italic>n</italic>
 = 4) as the presenting movement disorder was common in patients of French ancestry with 498InsTC mutations. Those with 460InsA mutations are unlikely to present with tremor and cerebellar ataxia.</p>
<fig id="f02" orientation="portrait" position="float">
<label>Figure 2</label>
<caption>
<title>Initial Presentations of Neuroferritinopathy Patients with Respective Mutations in Reported Symptomatic Cases. Chorea (39.7%) and dystonia (38.5%) are the most common initial presentations, followed by tremor (7.2%), parkinsonism (6%), cerebellar ataxia (4.8%), psychiatric symptoms (2.4%) and tics (1.2%). The associated mutations are listed alongside the symptoms.</title>
</caption>
<graphic xlink:href="tre-06-355-7522-1-g002"></graphic>
</fig>
<p>The abnormal movements may remain asymmetric throughout the disease course in almost two-thirds of patients.
<xref rid="b02" ref-type="bibr">2</xref>
Irrespective of the initial presentation, most patients develop dystonia (83%), predominantly in the lower limbs, and/or chorea (70%).
<xref rid="b02" ref-type="bibr">2</xref>
Cerebellar symptoms such as dysmetria, ataxia, and palatal tremor are reported in patients with NF and may appear at any stage of the disease.
<xref rid="b02" ref-type="bibr">2</xref>
,
<xref rid="b13" ref-type="bibr">13</xref>
,
<xref rid="b14" ref-type="bibr">14</xref>
,
<xref rid="b16" ref-type="bibr">16</xref>
,
<xref rid="b17" ref-type="bibr">17</xref>
,
<xref rid="b20" ref-type="bibr">20</xref>
,
<xref rid="b22" ref-type="bibr">22</xref>
,
<xref rid="b23" ref-type="bibr">23</xref>
,
<xref rid="b26" ref-type="bibr">26</xref>
,
<xref rid="b31" ref-type="bibr">31</xref>
Although unsteady gait and repeated falls may appear early in NF,
<xref rid="b14" ref-type="bibr">14</xref>
,
<xref rid="b27" ref-type="bibr">27</xref>
the majority of patients remain mobile even after 20 years of disease onset.
<xref rid="b02" ref-type="bibr">2</xref>
Patients with dystonic presentation have the most severe physical disability.
<xref rid="b02" ref-type="bibr">2</xref>
Dysarthria and dysphagia have been reported in many patients.
<xref rid="b02" ref-type="bibr">2</xref>
,
<xref rid="b16" ref-type="bibr">16</xref>
,
<xref rid="b19" ref-type="bibr">19</xref>
,
<xref rid="b20" ref-type="bibr">20</xref>
,
<xref rid="b22" ref-type="bibr">22</xref>
,
<xref rid="b26" ref-type="bibr">26</xref>
,
<xref rid="b27" ref-type="bibr">27</xref>
,
<xref rid="b30" ref-type="bibr">30</xref>
,
<xref rid="b34" ref-type="bibr">34</xref>
Oromandibular dyskinesia (65%), impairment of voice and speech (dysarthrophonia) with action-specific facial dystonia (63%) are commonly seen,
<xref rid="b02" ref-type="bibr">2</xref>
,
<xref rid="b13" ref-type="bibr">13</xref>
,
<xref rid="b20" ref-type="bibr">20</xref>
,
<xref rid="b22" ref-type="bibr">22</xref>
,
<xref rid="b24" ref-type="bibr">24</xref>
and felt by one group to be specific to NF.
<xref rid="b24" ref-type="bibr">24</xref>
Facial tics may be seen.
<xref rid="b26" ref-type="bibr">26</xref>
Although changes in handwriting are expected to occur in most of the patients, micrographia has been specifically reported.
<xref rid="b16" ref-type="bibr">16</xref>
Rarely, patients may present with ballistic movements,
<xref rid="b02" ref-type="bibr">2</xref>
alien limb phenomenon,
<xref rid="b02" ref-type="bibr">2</xref>
blepharospasm,
<xref rid="b02" ref-type="bibr">2</xref>
,
<xref rid="b24" ref-type="bibr">24</xref>
,
<xref rid="b30" ref-type="bibr">30</xref>
or writer’s cramp.
<xref rid="b02" ref-type="bibr">2</xref>
</p>
<p>Pyramidal signs including spasticity,
<xref rid="b01" ref-type="bibr">1</xref>
brisk deep tendon reflexes,
<xref rid="b32" ref-type="bibr">32</xref>
and Babinski signs
<xref rid="b13" ref-type="bibr">13</xref>
,
<xref rid="b16" ref-type="bibr">16</xref>
,
<xref rid="b22" ref-type="bibr">22</xref>
have been reported in patients with NF. Hypotonia may be seen.
<xref rid="b19" ref-type="bibr">19</xref>
,
<xref rid="b22" ref-type="bibr">22</xref>
,
<xref rid="b32" ref-type="bibr">32</xref>
Although extraocular movements are usually well preserved, some patients may develop saccadic pursuit,
<xref rid="b02" ref-type="bibr">2</xref>
,
<xref rid="b16" ref-type="bibr">16</xref>
,
<xref rid="b23" ref-type="bibr">23</xref>
slow saccades,
<xref rid="b16" ref-type="bibr">16</xref>
,
<xref rid="b22" ref-type="bibr">22</xref>
,
<xref rid="b23" ref-type="bibr">23</xref>
and apraxia of eyelid opening.
<xref rid="b16" ref-type="bibr">16</xref>
,
<xref rid="b23" ref-type="bibr">23</xref>
Limitation of vertical eye movements
<xref rid="b20" ref-type="bibr">20</xref>
and horizontal oculomotor dysmetria
<xref rid="b21" ref-type="bibr">21</xref>
are reported.</p>
</sec>
<sec id="s3b">
<title>Cognitive decline and psychiatric symptoms</title>
<p>The onset of cognitive impairment may vary from the first decade to more than three decades after the onset of motor symptoms.
<xref rid="b02" ref-type="bibr">2</xref>
,
<xref rid="b13" ref-type="bibr">13</xref>
<xref rid="b15" ref-type="bibr">15</xref>
,
<xref rid="b19" ref-type="bibr">19</xref>
,
<xref rid="b21" ref-type="bibr">21</xref>
,
<xref rid="b25" ref-type="bibr">25</xref>
,
<xref rid="b32" ref-type="bibr">32</xref>
,
<xref rid="b34" ref-type="bibr">34</xref>
One study reported neurocognitive features presenting within 5 years of onset of the motor manifestations.
<xref rid="b34" ref-type="bibr">34</xref>
Mild deficits in verbal fluency may be seen early.
<xref rid="b02" ref-type="bibr">2</xref>
Features suggestive of frontal and subcortical cognitive impairment like disinhibition, reduced verbal fluency, executive dysfunction (working memory), and attention difficulties predominate.
<xref rid="b02" ref-type="bibr">2</xref>
,
<xref rid="b13" ref-type="bibr">13</xref>
,
<xref rid="b15" ref-type="bibr">15</xref>
,
<xref rid="b21" ref-type="bibr">21</xref>
,
<xref rid="b25" ref-type="bibr">25</xref>
Rarely, patients may present with psychiatric symptoms (2.4%;
<italic>n</italic>
 = 2) (
<xref ref-type="fig" rid="f02">Figure 2</xref>
). Japanese patients presented more commonly with psychiatric symptoms and cognitive decline. Anxiety,
<xref rid="b13" ref-type="bibr">13</xref>
paranoid delusions,
<xref rid="b35" ref-type="bibr">35</xref>
acute psychosis,
<xref rid="b17" ref-type="bibr">17</xref>
or depression
<xref rid="b16" ref-type="bibr">16</xref>
,
<xref rid="b19" ref-type="bibr">19</xref>
,
<xref rid="b20" ref-type="bibr">20</xref>
have been reported to occur anytime in the course of NF.</p>
</sec>
<sec id="s3c">
<title>Other features</title>
<p>Sleep disturbances, including insomnia,
<xref rid="b13" ref-type="bibr">13</xref>
sleep apnea,
<xref rid="b35" ref-type="bibr">35</xref>
and central sleep apnea with restrictive respiratory insufficiency causing excessive daytime sleepiness,
<xref rid="b20" ref-type="bibr">20</xref>
have been reported. Other features may include areflexia and a positive Romberg test;
<xref rid="b16" ref-type="bibr">16</xref>
features of dyautonomia such as othostatic hypotension,
<xref rid="b20" ref-type="bibr">20</xref>
,
<xref rid="b22" ref-type="bibr">22</xref>
constipation,
<xref rid="b20" ref-type="bibr">20</xref>
urinary incontinence
<xref rid="b20" ref-type="bibr">20</xref>
and impotence;
<xref rid="b16" ref-type="bibr">16</xref>
fatigue
<xref rid="b16" ref-type="bibr">14</xref>
and pseudobulbar effect.
<xref rid="b16" ref-type="bibr">16</xref>
,
<xref rid="b19" ref-type="bibr">19</xref>
,
<xref rid="b22" ref-type="bibr">22</xref>
Chronic headache may also be a presenting symptom.
<xref rid="b22" ref-type="bibr">22</xref>
Sensory abnormalities in the large fiber sensations (vibration and proprioception) and positive frontal release signs have been reported.
<xref rid="b26" ref-type="bibr">26</xref>
</p>
</sec>
</sec>
<sec id="s4">
<title>Differential diagnoses</title>
<p>The varied clinical presentations of NF make for a long list of differential diagnoses. Common differential diagnoses are listed in
<xref ref-type="table" rid="t02">Table 2</xref>
. Others may include Niemann–Pick type C (NPC) and mitochondrial disease.
<xref rid="b02" ref-type="bibr">2</xref>
Marked supranuclear gaze impairment favors a diagnosis of NPC.
<xref rid="b02" ref-type="bibr">2</xref>
Although there are overlaps in the clinical, radiological, and muscle biopsy findings between NF and mitochondrial disorders, positive genetic testing for
<italic>FTL1</italic>
mutation confirms the diagnosis of NF.
<xref rid="b02" ref-type="bibr">2</xref>
Additional brain immunocytochemical abnormalities indicate a secondary defect of the respiratory chain in NF.
<xref rid="b16" ref-type="bibr">16</xref>
Early in the course of NF, patients may present with features of writer’s cramp, blepharospasm, or restless leg syndrome.
<xref rid="b02" ref-type="bibr">2</xref>
A family history of NF, decreased serum ferritin, and magnetic resonance imaging (MRI) brain suggestive of abnormal iron storage in the basal ganglia may point to the diagnosis of NF in such patients.
<xref rid="b02" ref-type="bibr">2</xref>
</p>
<p>
<table-wrap id="t02" orientation="portrait" position="float">
<label>Table 2</label>
<caption>
<title>Common Differential Diagnoses of Neuroferritinopathy</title>
</caption>
<table frame="hsides" rules="groups" width="95%">
<thead style="border-bottom: thin solid; border-top: thin solid; border-color: #000000">
<tr>
<th align="left" rowspan="2" colspan="1">Inheritance Pattern</th>
<th align="left" rowspan="2" colspan="1">Disease</th>
<th align="center" colspan="3" rowspan="1">Similarities</th>
<th align="center" colspan="3" rowspan="1">Differences</th>
</tr>
<tr>
<th align="left" rowspan="1" colspan="1">Clinical</th>
<th align="left" rowspan="1" colspan="1">Radiology</th>
<th align="left" rowspan="1" colspan="1">Pathology and Biochem.</th>
<th align="left" rowspan="1" colspan="1">Clinical</th>
<th align="left" rowspan="1" colspan="1">Radiology</th>
<th align="left" rowspan="1" colspan="1">Pathology and Biochem.</th>
</tr>
</thead>
<tbody style="border-color: #000000; border-bottom: thin solid">
<tr>
<td valign="top" align="left" rowspan="1" colspan="1">Autosomal recessive</td>
<td valign="top" align="left" rowspan="1" colspan="1">PKAN
<xref rid="b03" ref-type="bibr">3</xref>
,
<xref rid="b36" ref-type="bibr">36</xref>
</td>
<td valign="top" align="left" rowspan="1" colspan="1">
<list list-type="bullet">
<list-item>
<p>Ataxia</p>
</list-item>
<list-item>
<p>Dystonia</p>
</list-item>
<list-item>
<p>Tremor</p>
</list-item>
<list-item>
<p>Cognitive decline</p>
</list-item>
</list>
</td>
<td valign="top" align="left" rowspan="1" colspan="1">
<list list-type="bullet">
<list-item>
<p>T2 decr. in GP</p>
</list-item>
</list>
</td>
<td valign="top" align="left" rowspan="1" colspan="1">
<list list-type="bullet">
<list-item>
<p>Iron and ferritin deposition in BG</p>
</list-item>
</list>
</td>
<td valign="top" align="left" rowspan="1" colspan="1">
<list list-type="bullet">
<list-item>
<p>Onset before 6 years in 90%</p>
</list-item>
<list-item>
<p>Early cognitive, psychiatric and bulbar involvement</p>
</list-item>
<list-item>
<p>Oculomotor and retinal abnormalities</p>
</list-item>
</list>
</td>
<td valign="top" align="left" rowspan="1" colspan="1">
<list list-type="bullet">
<list-item>
<p>Classic “eye of the tiger” sign, central T2 incr. and surrounding decr. in GP</p>
</list-item>
</list>
</td>
<td valign="top" align="left" rowspan="1" colspan="1">
<list list-type="bullet">
<list-item>
<p>No cavitations</p>
</list-item>
<list-item>
<p>Cortex, brainstem, and cerebellum not involved</p>
</list-item>
</list>
</td>
</tr>
<tr>
<td valign="top" align="center" rowspan="1" colspan="1"></td>
<td valign="top" align="left" rowspan="1" colspan="1">Aceruloplasminemia
<xref rid="b03" ref-type="bibr">3</xref>
,
<xref rid="b36" ref-type="bibr">36</xref>
</td>
<td valign="top" align="left" rowspan="1" colspan="1">
<list list-type="bullet">
<list-item>
<p>Dystonia</p>
</list-item>
<list-item>
<p>Dysarthria</p>
</list-item>
<list-item>
<p>Ataxia</p>
</list-item>
<list-item>
<p>Cognitive decline</p>
</list-item>
</list>
</td>
<td valign="top" align="left" rowspan="1" colspan="1">
<list list-type="bullet">
<list-item>
<p>T2 decr. in GP</p>
</list-item>
</list>
</td>
<td valign="top" align="left" rowspan="1" colspan="1">
<list list-type="bullet">
<list-item>
<p>Iron deposition in brain (BG, DN, Th, cerebral, and cerebellar cortices)</p>
</list-item>
</list>
</td>
<td valign="top" align="left" rowspan="1" colspan="1">
<list list-type="bullet">
<list-item>
<p>Diabetes</p>
</list-item>
<list-item>
<p>Anemia</p>
</list-item>
<list-item>
<p>Early cognitive decline</p>
</list-item>
<list-item>
<p>Ataxia more common</p>
</list-item>
<list-item>
<p>Retinal involvement</p>
</list-item>
</list>
</td>
<td valign="top" align="left" rowspan="1" colspan="1">
<list list-type="bullet">
<list-item>
<p>T2 decr. in DN, SN, CN, P, Th, and cerebral cortex</p>
</list-item>
<list-item>
<p>No cavitation</p>
</list-item>
</list>
</td>
<td valign="top" align="left" rowspan="1" colspan="1">
<list list-type="bullet">
<list-item>
<p>Iron deposition in retina, pancreas, and liver in all patients</p>
</list-item>
<list-item>
<p>Incr. serum ferritin</p>
</list-item>
</list>
</td>
</tr>
<tr>
<td valign="top" align="center" rowspan="1" colspan="1"></td>
<td valign="top" align="left" rowspan="1" colspan="1">Wilson’s disease
<xref rid="b37" ref-type="bibr">37</xref>
,
<xref rid="b38" ref-type="bibr">38</xref>
</td>
<td valign="top" align="left" rowspan="1" colspan="1">
<list list-type="bullet">
<list-item>
<p>Dystonia</p>
</list-item>
<list-item>
<p>Chorea</p>
</list-item>
<list-item>
<p>Parkinsonism</p>
</list-item>
<list-item>
<p>Ataxia</p>
</list-item>
</list>
</td>
<td valign="top" align="left" rowspan="1" colspan="1">
<list list-type="bullet">
<list-item>
<p>Cortical, cerebellar and BG atrophy</p>
</list-item>
</list>
</td>
<td valign="top" align="left" rowspan="1" colspan="1">
<list list-type="bullet">
<list-item>
<p>Iron deposition in BG</p>
</list-item>
<list-item>
<p>Putaminal cavitation</p>
</list-item>
</list>
</td>
<td valign="top" align="left" rowspan="1" colspan="1">
<list list-type="bullet">
<list-item>
<p>Young onset</p>
</list-item>
<list-item>
<p>Early psychiatric and hepatic features</p>
</list-item>
<list-item>
<p>Corneal K-F rings</p>
</list-item>
</list>
</td>
<td valign="top" align="left" rowspan="1" colspan="1">
<list list-type="bullet">
<list-item>
<p>T2 incr. in P, GP, CN, and Th.</p>
</list-item>
<list-item>
<p>“Face of giant Panda” sign in mid-brain (T2 incr. around RN)</p>
</list-item>
</list>
</td>
<td valign="top" align="left" rowspan="1" colspan="1">
<list list-type="bullet">
<list-item>
<p>Copper deposition in BG</p>
</list-item>
<list-item>
<p>Decr. serum ceruloplasmin and increased 24-hour urinary copper</p>
</list-item>
</list>
</td>
</tr>
<tr>
<td valign="top" align="center" rowspan="1" colspan="1"></td>
<td valign="top" align="left" rowspan="1" colspan="1">Chorea-acanthocytosis
<xref rid="b39" ref-type="bibr">39</xref>
</td>
<td valign="top" align="left" rowspan="1" colspan="1">
<list list-type="bullet">
<list-item>
<p>Chorea</p>
</list-item>
<list-item>
<p>Orofacial dyskinesia</p>
</list-item>
<list-item>
<p>Dystonia</p>
</list-item>
<list-item>
<p>Tics</p>
</list-item>
<list-item>
<p>Parkinsonism</p>
</list-item>
</list>
</td>
<td valign="top" align="left" rowspan="1" colspan="1">
<list list-type="bullet">
<list-item>
<p>BG atrophy</p>
</list-item>
</list>
</td>
<td valign="top" align="left" rowspan="1" colspan="1">
<list list-type="bullet">
<list-item>
<p>Neuronal loss and gliosis in the striatum, GP and SN</p>
</list-item>
</list>
</td>
<td valign="top" align="left" rowspan="1" colspan="1">
<list list-type="bullet">
<list-item>
<p>AR</p>
</list-item>
<list-item>
<p>Young adult onset</p>
</list-item>
<list-item>
<p>Seizures</p>
</list-item>
<list-item>
<p>Tics more common</p>
</list-item>
<list-item>
<p>Self-mutilation</p>
</list-item>
<list-item>
<p>Oculomotor abnormalities</p>
</list-item>
<list-item>
<p>Myopathy</p>
</list-item>
<list-item>
<p>Neuropathy</p>
</list-item>
</list>
</td>
<td valign="top" align="left" rowspan="1" colspan="1">
<list list-type="bullet">
<list-item>
<p>Caudate atrophy (predilection for the head of CN)</p>
</list-item>
</list>
</td>
<td valign="top" align="left" rowspan="1" colspan="1">
<list list-type="bullet">
<list-item>
<p>Acanthocytes in peripheral blood smear</p>
</list-item>
<list-item>
<p>Elevated CK</p>
</list-item>
</list>
</td>
</tr>
<tr>
<td valign="top" rowspan="1" align="center" colspan="1">Autosomal dominant</td>
<td valign="top" align="left" rowspan="1" colspan="1">HD
<xref rid="b04" ref-type="bibr">4</xref>
,
<xref rid="b40" ref-type="bibr">40</xref>
</td>
<td valign="top" align="left" rowspan="1" colspan="1">
<list list-type="bullet">
<list-item>
<p>Chorea</p>
</list-item>
<list-item>
<p>Tics</p>
</list-item>
<list-item>
<p>Ataxia</p>
</list-item>
<list-item>
<p>Parkinsonism (Westphal variant)</p>
</list-item>
</list>
</td>
<td valign="top" align="left" rowspan="1" colspan="1">
<list list-type="bullet">
<list-item>
<p>Mild cortical atrophy</p>
</list-item>
</list>
</td>
<td valign="top" align="left" rowspan="1" colspan="1">
<list list-type="bullet">
<list-item>
<p>May have iron accumulation in BG</p>
</list-item>
</list>
</td>
<td valign="top" align="left" rowspan="1" colspan="1">
<list list-type="bullet">
<list-item>
<p>Genetic anticipation
<xref ref-type="table-fn" rid="TFN02t02">
<sup>1</sup>
</xref>
</p>
</list-item>
<list-item>
<p>Early personality changes and cognitive impairment</p>
</list-item>
<list-item>
<p>Tics common</p>
</list-item>
</list>
</td>
<td valign="top" align="left" rowspan="1" colspan="1">
<list list-type="bullet">
<list-item>
<p>Caudate atrophy (tail and body of CN)</p>
</list-item>
</list>
</td>
<td valign="top" align="left" rowspan="1" colspan="1">
<list list-type="bullet">
<list-item>
<p>Atrophy mainly in BG</p>
</list-item>
</list>
</td>
</tr>
<tr>
<td valign="top" align="center" rowspan="1" colspan="1"></td>
<td valign="top" align="left" rowspan="1" colspan="1">DRPLA
<xref rid="b40" ref-type="bibr">40</xref>
</td>
<td valign="top" align="left" rowspan="1" colspan="1">
<list list-type="bullet">
<list-item>
<p>Chorea</p>
</list-item>
<list-item>
<p>Ataxia</p>
</list-item>
<list-item>
<p>Cognitive and psychiatric features</p>
</list-item>
</list>
</td>
<td valign="top" align="left" rowspan="1" colspan="1">
<list list-type="bullet">
<list-item>
<p>Cerebellar atrophy</p>
</list-item>
</list>
</td>
<td valign="top" align="left" rowspan="1" colspan="1">
<list list-type="bullet">
<list-item>
<p>None specific</p>
</list-item>
</list>
</td>
<td valign="top" align="left" rowspan="1" colspan="1">
<list list-type="bullet">
<list-item>
<p>Genetic anticipation
<xref ref-type="table-fn" rid="TFN02t02">
<sup>1</sup>
</xref>
</p>
</list-item>
<list-item>
<p>Epilepsy and myoclonus</p>
</list-item>
</list>
</td>
<td valign="top" align="left" rowspan="1" colspan="1">
<list list-type="bullet">
<list-item>
<p>Pontine tegmental atrophy</p>
</list-item>
</list>
</td>
<td valign="top" align="left" rowspan="1" colspan="1">
<list list-type="bullet">
<list-item>
<p>None specific</p>
</list-item>
</list>
</td>
</tr>
<tr>
<td valign="top" align="center" rowspan="1" colspan="1"></td>
<td valign="top" align="left" rowspan="1" colspan="1">SCA
<xref rid="b40" ref-type="bibr">40</xref>
,
<xref rid="b41" ref-type="bibr">41</xref>
</td>
<td valign="top" align="left" rowspan="1" colspan="1">
<list list-type="bullet">
<list-item>
<p>Ataxia</p>
</list-item>
<list-item>
<p>Pyramidal signs</p>
</list-item>
<list-item>
<p>Chorea (SCA 17)</p>
</list-item>
</list>
</td>
<td valign="top" align="left" rowspan="1" colspan="1">
<list list-type="bullet">
<list-item>
<p>Cerebellar atrophy</p>
</list-item>
</list>
</td>
<td valign="top" align="left" rowspan="1" colspan="1">
<list list-type="bullet">
<list-item>
<p>None specific</p>
</list-item>
</list>
</td>
<td valign="top" align="left" rowspan="1" colspan="1">
<list list-type="bullet">
<list-item>
<p>Genetic anticipation
<xref ref-type="table-fn" rid="TFN02t02">
<sup>1</sup>
</xref>
</p>
</list-item>
<list-item>
<p>Marked ataxia</p>
</list-item>
<list-item>
<p>Nystagmus</p>
</list-item>
<list-item>
<p>Peripheral neuropathy</p>
</list-item>
<list-item>
<p>Myoclonus</p>
</list-item>
<list-item>
<p>Seizures</p>
</list-item>
</list>
</td>
<td valign="top" align="left" rowspan="1" colspan="1">
<list list-type="bullet">
<list-item>
<p>Marked cerebellar atrophy</p>
</list-item>
</list>
</td>
<td valign="top" align="left" rowspan="1" colspan="1">
<list list-type="bullet">
<list-item>
<p>None specific</p>
</list-item>
</list>
</td>
</tr>
<tr>
<td valign="top" rowspan="2" align="center" colspan="1">Sporadic/mixed (AR and AD)</td>
<td valign="top" align="left" rowspan="1" colspan="1">Isolated or combined dystonia syndromes
<xref rid="b42" ref-type="bibr">42</xref>
</td>
<td valign="top" align="left" rowspan="1" colspan="1">
<list list-type="bullet">
<list-item>
<p>Focal or generalized dystonia</p>
</list-item>
<list-item>
<p>Parkinsonism</p>
</list-item>
</list>
</td>
<td valign="top" align="left" rowspan="1" colspan="1">
<list list-type="bullet">
<list-item>
<p>None specific</p>
</list-item>
</list>
</td>
<td valign="top" align="left" rowspan="1" colspan="1">
<list list-type="bullet">
<list-item>
<p>None specific</p>
</list-item>
</list>
</td>
<td valign="top" align="left" rowspan="1" colspan="1">
<list list-type="bullet">
<list-item>
<p>Childhood onset</p>
</list-item>
<list-item>
<p>Myoclonus</p>
</list-item>
<list-item>
<p>Normal cognition</p>
</list-item>
<list-item>
<p>DRD is levodopa responsive</p>
</list-item>
</list>
</td>
<td valign="top" align="left" rowspan="1" colspan="1">
<list list-type="bullet">
<list-item>
<p>None specific</p>
</list-item>
</list>
</td>
<td valign="top" align="left" rowspan="1" colspan="1">
<list list-type="bullet">
<list-item>
<p>None specific</p>
</list-item>
</list>
</td>
</tr>
<tr>
<td valign="top" align="left" rowspan="1" colspan="1">Parkinsonism (IPD, parkin mutation)
<xref rid="b04" ref-type="bibr">4</xref>
,
<xref rid="b43" ref-type="bibr">43</xref>
</td>
<td valign="top" align="left" rowspan="1" colspan="1">
<list list-type="bullet">
<list-item>
<p>Parkinsonism</p>
</list-item>
</list>
</td>
<td valign="top" align="left" rowspan="1" colspan="1">
<list list-type="bullet">
<list-item>
<p>None specific</p>
</list-item>
</list>
</td>
<td valign="top" align="left" rowspan="1" colspan="1">
<list list-type="bullet">
<list-item>
<p>Iron deposition may be seen in SN</p>
</list-item>
</list>
</td>
<td valign="top" align="left" rowspan="1" colspan="1">
<list list-type="bullet">
<list-item>
<p>Levodopa responsive</p>
</list-item>
</list>
</td>
<td valign="top" align="left" rowspan="1" colspan="1">
<list list-type="bullet">
<list-item>
<p>None specific</p>
</list-item>
</list>
</td>
<td valign="top" align="left" rowspan="1" colspan="1">
<list list-type="bullet">
<list-item>
<p>None specific</p>
</list-item>
</list>
</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="TFN01t02">
<p>Abbreviations: AD, Autosomal Dominant; AR, Autosomal Recessive; BG, Basal Ganglia; Biochem., Biochemical Parameters; CK, Creatine Kinase; CN, Caudate Nucleus; Decr., Decreased; DN, Dentate Nucleus; DRD, Dopa-responsive Dystonia; DRPLA, Dentato-Rubral-Pallido-Luysian Atrophy; GP, Globus Pallidus; HD, Huntington’s Disease; Incr., Increased; IPD, Idiopathic Parkinson Disease; K-F rings, Kayser–Fleischer Rings; P, Putamen; PD, Parkinson Disease; PKAN, Pantothenate Kinase-associated Neurodegeneration; RN, Red Nucleus; SCA, Spinocerebellar Ataxia; SN, Substantia Nigra; Th, Thalamus.</p>
</fn>
<fn id="TFN02t02">
<label>1</label>
<p>In successive generations, there may be an increase in the number of trinucleotide repeats in the affected gene leading to earlier age of onset.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</p>
</sec>
<sec id="s5">
<title>Investigations</title>
<sec id="s5a">
<title>Laboratory investigations</title>
<p>Complete blood count, renal function tests, copper studies (serum ceruloplasmin and copper, and 24-hour urinary copper), and serum creatine kinase are typically normal in NF.
<xref rid="b01" ref-type="bibr">1</xref>
,
<xref rid="b02" ref-type="bibr">2</xref>
,
<xref rid="b15" ref-type="bibr">15</xref>
,
<xref rid="b23" ref-type="bibr">23</xref>
,
<xref rid="b35" ref-type="bibr">35</xref>
Liver function tests may be abnormal.
<xref rid="b13" ref-type="bibr">13</xref>
Serum ferritin levels may be decreased
<xref rid="b01" ref-type="bibr">1</xref>
,
<xref rid="b02" ref-type="bibr">2</xref>
,
<xref rid="b14" ref-type="bibr">14</xref>
,
<xref rid="b17" ref-type="bibr">17</xref>
,
<xref rid="b20" ref-type="bibr">20</xref>
,
<xref rid="b21" ref-type="bibr">21</xref>
,
<xref rid="b32" ref-type="bibr">32</xref>
or in the normal range.
<xref rid="b16" ref-type="bibr">16</xref>
,
<xref rid="b19" ref-type="bibr">19</xref>
,
<xref rid="b22" ref-type="bibr">22</xref>
,
<xref rid="b23" ref-type="bibr">23</xref>
,
<xref rid="b35" ref-type="bibr">35</xref>
Although decreased serum ferritin was not uniformly seen in all the cases, a low serum ferritin in the setting of an unknown movement disorder with autosomal dominant family history suggests the diagnosis of NF. In the largest series of patients, the serum ferritin was decreased in 82% of males and all postmenopausal females, but only in 23% of premenopausal females.
<xref rid="b02" ref-type="bibr">2</xref>
This may be explained because of the loss of iron owing to menstruation in premenopausal females.
<xref rid="b02" ref-type="bibr">2</xref>
,
<xref rid="b19" ref-type="bibr">19</xref>
Decreased CSF ferritin was reported by Nishida et al.
<xref rid="b22" ref-type="bibr">22</xref>
Nerve conduction studies are normal.
<xref rid="b23" ref-type="bibr">23</xref>
</p>
</sec>
<sec id="s5b">
<title>Neuroimaging</title>
<p>Key features on brain imaging support the diagnostic consideration of NF.
<xref rid="b11" ref-type="bibr">11</xref>
Features of iron deposition precede evidence of atrophy and necrosis on brain MRI.
<xref rid="b29" ref-type="bibr">29</xref>
,
<xref rid="b36" ref-type="bibr">36</xref>
Brain MRI may show basal ganglia cavitation or cystic changes (predominantly in the globus pallidus and putamen),
<xref rid="b01" ref-type="bibr">1</xref>
,
<xref rid="b15" ref-type="bibr">15</xref>
,
<xref rid="b16" ref-type="bibr">16</xref>
,
<xref rid="b18" ref-type="bibr">18</xref>
,
<xref rid="b20" ref-type="bibr">20</xref>
,
<xref rid="b21" ref-type="bibr">21</xref>
,
<xref rid="b28" ref-type="bibr">28</xref>
,
<xref rid="b29" ref-type="bibr">29</xref>
,
<xref rid="b36" ref-type="bibr">36</xref>
hyperintensity with surrounding hypointensity on T2-weighted imaging involving the putamen, pallidum, thalamus, substantia nigra, and the dentate nucleus,
<xref rid="b02" ref-type="bibr">2</xref>
,
<xref rid="b18" ref-type="bibr">18</xref>
,
<xref rid="b19" ref-type="bibr">19</xref>
,
<xref rid="b22" ref-type="bibr">22</xref>
,
<xref rid="b23" ref-type="bibr">23</xref>
,
<xref rid="b35" ref-type="bibr">35</xref>
cortical atrophy,
<xref rid="b13" ref-type="bibr">13</xref>
,
<xref rid="b14" ref-type="bibr">14</xref>
,
<xref rid="b17" ref-type="bibr">17</xref>
,
<xref rid="b23" ref-type="bibr">23</xref>
,
<xref rid="b31" ref-type="bibr">31</xref>
pontine atrophy,
<xref rid="b13" ref-type="bibr">13</xref>
and cerebellar atrophy.
<xref rid="b13" ref-type="bibr">13</xref>
,
<xref rid="b16" ref-type="bibr">16</xref>
,
<xref rid="b28" ref-type="bibr">28</xref>
,
<xref rid="b31" ref-type="bibr">31</xref>
T2-weighted images showing a hypointense rim with hyperintense center in the globus pallidus (“eye of the tiger sign”), considered pathognomic of PKAN,
<xref rid="b03" ref-type="bibr">3</xref>
is reported in NF.
<xref rid="b22" ref-type="bibr">22</xref>
,
<xref rid="b36" ref-type="bibr">36</xref>
This MRI signature may also be seen in cortico-basal ganglionic degeneration, multiple system atrophy, progressive supranuclear palsy, and pure akinesia with gait freezing.
<xref rid="b22" ref-type="bibr">22</xref>
,
<xref rid="b36" ref-type="bibr">36</xref>
While thalamic iron stores correlate with the severity of dystonia,
<xref rid="b29" ref-type="bibr">29</xref>
voxel-based analysis showed correlation between caudate iron stores and globus pallidus cavitation to the severity in NF patients.
<xref rid="b28" ref-type="bibr">28</xref>
Iron deposition in the cortex,
<xref rid="b28" ref-type="bibr">28</xref>
,
<xref rid="b30" ref-type="bibr">30</xref>
,
<xref rid="b36" ref-type="bibr">36</xref>
on susceptibility-weighted imaging sequence on MRI, produces a hypointense fine signal band along the cortical contours and is termed “pencil-lining.”
<xref rid="b30" ref-type="bibr">30</xref>
Patients older than 50 years of age or those with disease duration of more than 10 years develop more severe basal ganglia cavitation.
<xref rid="b29" ref-type="bibr">29</xref>
Rarely, the brain MRI may be normal in the initial stage of the disease.
<xref rid="b35" ref-type="bibr">35</xref>
Asymptomatic persons with positive gene mutation may have abnormal brain MRI.
<xref rid="b17" ref-type="bibr">17</xref>
MRI brain findings in some patients with NF may remain asymmetric.
<xref rid="b16" ref-type="bibr">16</xref>
,
<xref rid="b21" ref-type="bibr">21</xref>
,
<xref rid="b25" ref-type="bibr">25</xref>
</p>
</sec>
<sec id="s5c">
<title>Genetic testing</title>
<p>Genetic testing for the
<italic>FTL1</italic>
gene mutation on chromosome 19q13.3 is confirmatory.
<xref rid="b11" ref-type="bibr">11</xref>
Rarely, the individual may be asymptomatic despite a confirmed mutation.
<xref rid="b02" ref-type="bibr">2</xref>
,
<xref rid="b17" ref-type="bibr">17</xref>
Of the nine causative
<italic>FTL1</italic>
mutations reported to date, 460InsA is the most common in patients of British descent and 498InsTC is common in patients with French ancestry. The 460InsA mutation has not been found in Japanese patients.</p>
</sec>
</sec>
<sec id="s6">
<title>Neuropathology</title>
<p>Mild cerebral and cerebellar atrophy with basal ganglia cavitation and numerous iron-positive inclusions especially in the globus pallidus and putamen are seen on neuropathological examination.
<xref rid="b01" ref-type="bibr">1</xref>
,
<xref rid="b13" ref-type="bibr">13</xref>
,
<xref rid="b16" ref-type="bibr">16</xref>
Intranuclear and intracytoplasmic ferritin deposition in astrocytes and oligodendroglia are seen in the caudate nucleus, putamen, globus pallidus, and in gray and white matter regions.
<xref rid="b13" ref-type="bibr">13</xref>
,
<xref rid="b16" ref-type="bibr">16</xref>
Ferritin deposits are also seen in cerebellar granule cells and Purkinje cells.
<xref rid="b13" ref-type="bibr">13</xref>
The ferritin deposits may be seen in the parenchymal cells of other organs like skin fibroblasts, renal tubule cells, and endothelial cells of muscle capillaries.
<xref rid="b13" ref-type="bibr">13</xref>
Intranuclear iron and ferritin inclusions are also found in hepatocytes.
<xref rid="b16" ref-type="bibr">16</xref>
This points to the fact that the pathology of NF is not limited to the brain tissue only and some authors suggested that “hereditary ferritinopathy” is a better term than the more restrictive “neuroferritinopathy.”
<xref rid="b04" ref-type="bibr">4</xref>
,
<xref rid="b13" ref-type="bibr">13</xref>
,
<xref rid="b16" ref-type="bibr">16</xref>
Muscle biopsy in a few NF patients showed evidence of mitochondrial respiratory chain defects.
<xref rid="b02" ref-type="bibr">2</xref>
,
<xref rid="b14" ref-type="bibr">14</xref>
<xref rid="b16" ref-type="bibr">16</xref>
Chinnery et al.
<xref rid="b02" ref-type="bibr">2</xref>
found a higher percentage of cytochrome
<italic>c</italic>
oxidase negative fibers than expected for age in two out of nine NF patients who underwent muscle biopsy. Respiratory chain complex assays reported in eight patients found isolated or combined defects in seven of them. While isolated defects in complex I
<xref rid="b02" ref-type="bibr">2</xref>
and complex III
<xref rid="b14" ref-type="bibr">14</xref>
were seen in three and one patient respectively, three other patients had a combined defect involving multiple respiratory chain complexes.
<xref rid="b02" ref-type="bibr">2</xref>
,
<xref rid="b16" ref-type="bibr">16</xref>
A generalized deficiency was reported in a sample of post-mortem cerebellar tissue.
<xref rid="b16" ref-type="bibr">16</xref>
These respiratory chain defects suggest mitochondrial dysfunction in NF.</p>
</sec>
<sec id="s7">
<title>Management</title>
<p>At present, there are no established guidelines or specific management recommendations for patients with NF.
<xref rid="b27" ref-type="bibr">27</xref>
An individualized symptomatic approach to treatment is recommended. A number of drugs have been used for symptomatic management in NF with variable success. Dystonia either showed some
<xref rid="b02" ref-type="bibr">2</xref>
,
<xref rid="b21" ref-type="bibr">21</xref>
,
<xref rid="b23" ref-type="bibr">23</xref>
,
<xref rid="b35" ref-type="bibr">35</xref>
or no
<xref rid="b14" ref-type="bibr">14</xref>
,
<xref rid="b16" ref-type="bibr">16</xref>
,
<xref rid="b19" ref-type="bibr">19</xref>
,
<xref rid="b22" ref-type="bibr">22</xref>
improvement with anticholinergics such as trihexyphenidyl. While variable improvement in chorea, tics, and stereotypy were reported with sulpiride (D2 receptor blocker) and tetrabenazine (dopamine depleting agent) in some patients, the latter is associated with complications including sedation, parkinsonism, and depression.
<xref rid="b02" ref-type="bibr">2</xref>
,
<xref rid="b26" ref-type="bibr">26</xref>
,
<xref rid="b27" ref-type="bibr">27</xref>
,
<xref rid="b35" ref-type="bibr">35</xref>
One report showed excellent response of facial tic/stereotype and chorea with tetrabenazine.
<xref rid="b26" ref-type="bibr">26</xref>
Parkinsonian symptoms of NF showed either no
<xref rid="b02" ref-type="bibr">2</xref>
,
<xref rid="b22" ref-type="bibr">22</xref>
,
<xref rid="b27" ref-type="bibr">27</xref>
or only some initial benefit
<xref rid="b20" ref-type="bibr">20</xref>
,
<xref rid="b35" ref-type="bibr">35</xref>
with levodopa. Benzodiazepines (diazepam, clonazepam, and lorazepam) have been shown to improve dystonia in a few patients,
<xref rid="b02" ref-type="bibr">2</xref>
,
<xref rid="b35" ref-type="bibr">35</xref>
but not in others.
<xref rid="b19" ref-type="bibr">19</xref>
,
<xref rid="b22" ref-type="bibr">22</xref>
Antidepressants, like fluoxetine, were helpful in treating depression.
<xref rid="b16" ref-type="bibr">16</xref>
,
<xref rid="b19" ref-type="bibr">19</xref>
Muscle relaxants, like baclofen, gave either partial
<xref rid="b35" ref-type="bibr">35</xref>
or no
<xref rid="b02" ref-type="bibr">2</xref>
,
<xref rid="b22" ref-type="bibr">22</xref>
benefit in treating dystonia. Various other drugs that have failed to improve the movement disorders include risperidone
<xref rid="b02" ref-type="bibr">2</xref>
, haloperidol,
<xref rid="b13" ref-type="bibr">13</xref>
,
<xref rid="b19" ref-type="bibr">19</xref>
,
<xref rid="b27" ref-type="bibr">27</xref>
tiapride,
<xref rid="b19" ref-type="bibr">19</xref>
olanzapine,
<xref rid="b02" ref-type="bibr">2</xref>
amitriptyline,
<xref rid="b02" ref-type="bibr">2</xref>
,
<xref rid="b16" ref-type="bibr">16</xref>
,
<xref rid="b35" ref-type="bibr">35</xref>
apomorphine,
<xref rid="b02" ref-type="bibr">2</xref>
,
<xref rid="b35" ref-type="bibr">35</xref>
amantadine,
<xref rid="b02" ref-type="bibr">2</xref>
dopamine agonists,
<xref rid="b14" ref-type="bibr">14</xref>
deanol,
<xref rid="b02" ref-type="bibr">2</xref>
dantrolene,
<xref rid="b02" ref-type="bibr">2</xref>
paroxetine,
<xref rid="b02" ref-type="bibr">2</xref>
mirtazapine,
<xref rid="b02" ref-type="bibr">2</xref>
gabapentin,
<xref rid="b02" ref-type="bibr">2</xref>
sodium valproate,
<xref rid="b02" ref-type="bibr">2</xref>
,
<xref rid="b22" ref-type="bibr">22</xref>
and carbamazepine.
<xref rid="b02" ref-type="bibr">2</xref>
,
<xref rid="b35" ref-type="bibr">35</xref>
One author reported improvement in the finger dystonia of a patient with herbal medicine (Shakuyaku-kanzo-to).
<xref rid="b22" ref-type="bibr">22</xref>
Physiotherapy in addition to drugs improved dystonia and gait in one patient.
<xref rid="b22" ref-type="bibr">22</xref>
Speech amplification may help hypophonia.
<xref rid="b02" ref-type="bibr">2</xref>
</p>
<p>Moderate benefits have been reported with the use of botulinum toxin for dystonia affecting the neck, orofacial region (including blepharospasm), and extremities.
<xref rid="b02" ref-type="bibr">2</xref>
,
<xref rid="b16" ref-type="bibr">16</xref>
,
<xref rid="b21" ref-type="bibr">21</xref>
,
<xref rid="b35" ref-type="bibr">35</xref>
Other symptomatic treatments include non-invasive positive pressure ventilation for sleep apnea and percutaneous endoscopic gastrostomy feeding for severe weight loss due to dysphagia.
<xref rid="b20" ref-type="bibr">20</xref>
,
<xref rid="b27" ref-type="bibr">27</xref>
Dysphagia should be monitored and managed with swallowing assessment and dietary modification.
<xref rid="b02" ref-type="bibr">2</xref>
</p>
<p>A number of treatments have been used for modulating the brain iron stores in the hope of reversing the pathology, but none have been reported to be successful. A low-iron diet did not show benefit after 6 months of its institution.
<xref rid="b16" ref-type="bibr">16</xref>
Iron chelation therapy with desferrioxamine (4,000 mg weekly subcutaneously for up to 14 months)
<xref rid="b02" ref-type="bibr">2</xref>
and deferiprone (15 mg/kg/day for 6 months) have not been effective.
<xref rid="b02" ref-type="bibr">2</xref>
,
<xref rid="b14" ref-type="bibr">14</xref>
No improvement was seen with monthly venesection.
<xref rid="b02" ref-type="bibr">2</xref>
,
<xref rid="b16" ref-type="bibr">16</xref>
,
<xref rid="b19" ref-type="bibr">19</xref>
Although no benefit has been reported in the short term with iron-modulating therapies, the long-term response has yet to be studied.</p>
<p>Although NF progresses gradually but relentlessly in most of the patients,
<xref rid="b02" ref-type="bibr">2</xref>
,
<xref rid="b13" ref-type="bibr">13</xref>
patients with a 458dupA mutation show a relatively rapid progression of parkinsonism, ataxia, and neuropsychiatric symptoms.
<xref rid="b20" ref-type="bibr">20</xref>
Patients usually die of aspiration pneumonia.
<xref rid="b16" ref-type="bibr">16</xref>
,
<xref rid="b19" ref-type="bibr">19</xref>
Other reported causes of death include community-acquired pneumonia,
<xref rid="b27" ref-type="bibr">27</xref>
asphyxiation of food,
<xref rid="b19" ref-type="bibr">19</xref>
and cardiomyopathy.
<xref rid="b20" ref-type="bibr">20</xref>
It is not known whether this last cause was related to NF.</p>
</sec>
<sec id="s8">
<title>Conclusion</title>
<p>NF is a rare autosomal dominant disease with
<italic>FTL1</italic>
mutation leading to abnormal excessive iron accumulation in the brain (predominantly in the basal ganglia) and other organ systems. In people of British descent, the most common mutation is 460InsA. Nine variant mutations in the
<italic>FTL1</italic>
gene have been reported in various geographical regions. NF patients with mutations other than 460InsA appear to have an earlier age of onset. Although NF has heterogeneous clinical presentations, chorea and dystonia are the most common presenting symptoms; however, these are not specific to a mutation. There are however specific features that depend on the genetic mutation and hence on regional distribution as reviewed in this manuscript.</p>
<p>NF must be considered in patients presenting clinically as a relentlessly progressive movement disorder with variable phenotype and imaging evidence of iron deposition within the brain, decreased serum ferritin, and negative genetic testing for other more common movement disorders like Huntington’s disease. The
<italic>FTL1</italic>
gene mutation should be suspected despite the lack of a positive family history, as new genetic mutations of this gene may occur in any population. Brain MRI is helpful, even during the pre-symptomatic period in relatives of affected patients, and unilateral or asymmetric lesions do not exclude the diagnosis. Although MRI features may overlap with other NBIAs, basal ganglia cavitation and cortical “pencil-lining” on susceptibility-weighted imaging favors NF. Standard symptomatic drug treatment for specific movement disorders may be used with variable success. Chelation therapies have not been shown to be effective.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="supported-by">
<p>
<bold>Funding:</bold>
None.</p>
</fn>
<fn fn-type="financial-disclosure">
<p>
<bold>Financial Disclosures:</bold>
None.</p>
</fn>
<fn fn-type="conflict">
<p>
<bold>Conflict of Interests:</bold>
The authors report no conflict of interest.</p>
</fn>
<fn fn-type="conflict">
<p>
<bold>Ethics Statement:</bold>
This study was reviewed by the authors' institutional ethics committee and was considered exempted from further review.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="b01">
<label>1</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Curtis</surname>
<given-names>ARJ</given-names>
</name>
<name>
<surname>Fey</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Morris</surname>
<given-names>CM</given-names>
</name>
<etal>et al</etal>
</person-group>
<article-title>Mutation in the gene encoding ferritin light polypeptide causes dominant adult-onset basal ganglia disease</article-title>
<source>Nat Genet</source>
<year>2001</year>
<volume>28</volume>
<fpage>350</fpage>
<lpage>354</lpage>
<pub-id pub-id-type="pmid">11438811</pub-id>
</element-citation>
</ref>
<ref id="b02">
<label>2</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chinnery</surname>
<given-names>PF</given-names>
</name>
<name>
<surname>Crompton</surname>
<given-names>DE</given-names>
</name>
<name>
<surname>Birchall</surname>
<given-names>D</given-names>
</name>
<etal>et al</etal>
</person-group>
<article-title>Clinical features and natural history of neuroferritinopathy caused by the
<italic>FTL1</italic>
460InsA mutation</article-title>
<source>Brain</source>
<year>2007</year>
<volume>130</volume>
<fpage>110</fpage>
<lpage>119</lpage>
<pub-id pub-id-type="pmid">17142829</pub-id>
</element-citation>
</ref>
<ref id="b03">
<label>3</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schneider</surname>
<given-names>SA</given-names>
</name>
<name>
<surname>Dusek</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Hardy</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Westenberger</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Jankovic</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Bhatia</surname>
<given-names>KP</given-names>
</name>
</person-group>
<article-title>Genetics and pathophysiology of neurodegeneration with brain iron accumulation (NBIA)</article-title>
<source>Curr Neuropharmacol</source>
<year>2013</year>
<volume>11</volume>
<fpage>59</fpage>
<lpage>79</lpage>
<comment>doi:
<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.2174/157015913804999469">10.2174/157015913804999469</ext-link>
</comment>
<pub-id pub-id-type="pmid">23814539</pub-id>
</element-citation>
</ref>
<ref id="b04">
<label>4</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dusek</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Jankovic</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Le</surname>
<given-names>W</given-names>
</name>
</person-group>
<article-title>Iron dysregulation in movement disorders</article-title>
<source>Neurobiol Dis</source>
<year>2012</year>
<volume>46</volume>
<fpage>1</fpage>
<lpage>18</lpage>
<comment>doi:
<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.nbd.2011.12.054">10.1016/j.nbd.2011.12.054</ext-link>
</comment>
<pub-id pub-id-type="pmid">22266337</pub-id>
</element-citation>
</ref>
<ref id="b05">
<label>5</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Crichton</surname>
<given-names>RR</given-names>
</name>
<name>
<surname>Dexter</surname>
<given-names>DT</given-names>
</name>
<name>
<surname>Ward</surname>
<given-names>RJ</given-names>
</name>
</person-group>
<article-title>Brain iron metabolism and its perturbation in neurological diseases</article-title>
<source>J Neural Transm</source>
<year>2011</year>
<volume>118</volume>
<fpage>301</fpage>
<lpage>314</lpage>
<comment>doi:
<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1007/s00702-010-0470-z">10.1007/s00702-010-0470-z</ext-link>
</comment>
<pub-id pub-id-type="pmid">20809066</pub-id>
</element-citation>
</ref>
<ref id="b06">
<label>6</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ward</surname>
<given-names>RJ</given-names>
</name>
<name>
<surname>Zucca</surname>
<given-names>FA</given-names>
</name>
<name>
<surname>Duyn</surname>
<given-names>JH</given-names>
</name>
<name>
<surname>Crichton</surname>
<given-names>RR</given-names>
</name>
<name>
<surname>Zecca</surname>
<given-names>L</given-names>
</name>
</person-group>
<article-title>The role of iron in brain ageing and neurodegenerative disorders</article-title>
<source>Lancet Neurol</source>
<year>2014</year>
<volume>13</volume>
<fpage>1045</fpage>
<lpage>1060</lpage>
<comment>doi:
<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/S1474-4422(14)70117-6">10.1016/S1474-4422(14)70117-6</ext-link>
</comment>
<pub-id pub-id-type="pmid">25231526</pub-id>
</element-citation>
</ref>
<ref id="b07">
<label>7</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Levi</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Cozzi</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Arosio</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>Neuroferritinopathy: a neurodegenerative disorder associated with L-ferritin mutation</article-title>
<source>Best Pract Res Clin Haematol</source>
<year>2005</year>
<volume>18</volume>
<fpage>265</fpage>
<lpage>276</lpage>
<pub-id pub-id-type="pmid">15737889</pub-id>
</element-citation>
</ref>
<ref id="b08">
<label>8</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ramos</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Santos</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Pinto</surname>
<given-names>NR</given-names>
</name>
<name>
<surname>Mendes</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Magalhães</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Almeida</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Iron levels in the human brain: a post-mortem study of anatomical region differences and age-related changes</article-title>
<source>J Trace Elem Med Biol</source>
<year>2014</year>
<volume>28</volume>
<fpage>13</fpage>
<lpage>17</lpage>
<comment>doi:
<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.jtemb.2013.08.001">10.1016/j.jtemb.2013.08.001</ext-link>
</comment>
<pub-id pub-id-type="pmid">24075790</pub-id>
</element-citation>
</ref>
<ref id="b09">
<label>9</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Leitner</surname>
<given-names>DF</given-names>
</name>
<name>
<surname>Connor</surname>
<given-names>JR</given-names>
</name>
</person-group>
<article-title>Functional roles of transferrin in the brain</article-title>
<source>Biochim Biophys Acta</source>
<year>2012</year>
<volume>1820</volume>
<fpage>393</fpage>
<lpage>402</lpage>
<comment>doi:
<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.bbagen.2011.10.016">10.1016/j.bbagen.2011.10.016</ext-link>
</comment>
<pub-id pub-id-type="pmid">22138408</pub-id>
</element-citation>
</ref>
<ref id="b10">
<label>10</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dringen</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Bishop</surname>
<given-names>GM</given-names>
</name>
<name>
<surname>Koeppe</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Dang</surname>
<given-names>TN</given-names>
</name>
<name>
<surname>Robinson</surname>
<given-names>SR</given-names>
</name>
</person-group>
<article-title>The pivotal role of astrocytes in the metabolism of iron in the brain</article-title>
<source>Neurochem Res</source>
<year>2007</year>
<volume>32</volume>
<fpage>1884</fpage>
<lpage>1890</lpage>
<pub-id pub-id-type="pmid">17551833</pub-id>
</element-citation>
</ref>
<ref id="b11">
<label>11</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Levi</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Rovida</surname>
<given-names>E</given-names>
</name>
</person-group>
<article-title>Neuroferritinopathy: from ferritin structure modification to pathogenetic mechanism</article-title>
<source>Neurobiol Dis</source>
<year>2015</year>
<volume>81</volume>
<fpage>134</fpage>
<lpage>143</lpage>
<comment>doi:
<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.nbd.2015.02.007">10.1016/j.nbd.2015.02.007</ext-link>
</comment>
<pub-id pub-id-type="pmid">25772441</pub-id>
</element-citation>
</ref>
<ref id="b12">
<label>12</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Levi</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Finazzi</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>Neurodegeneration with brain iron accumulation: update on pathogenic mechanisms</article-title>
<source>Front Pharmacol</source>
<year>2014</year>
<volume>5</volume>
<fpage>1</fpage>
<lpage>20</lpage>
<comment>doi:
<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.3389/fphar.2014.00099">10.3389/fphar.2014.00099</ext-link>
</comment>
<pub-id pub-id-type="pmid">24478702</pub-id>
</element-citation>
</ref>
<ref id="b13">
<label>13</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vidal</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Ghetti</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Takao</surname>
<given-names>M</given-names>
</name>
<etal>et al</etal>
</person-group>
<article-title>Intracellular ferritin accumulation in neural and extraneural tissue characterizes a neurodegenerative disease associated with a mutation in the ferritin light polypeptide gene</article-title>
<source>J Neuropathol Exp Neurol</source>
<year>2004</year>
<volume>63</volume>
<fpage>363</fpage>
<lpage>380</lpage>
<pub-id pub-id-type="pmid">15099026</pub-id>
</element-citation>
</ref>
<ref id="b14">
<label>14</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Storti</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Cortese</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Di Fabio</surname>
<given-names>R</given-names>
</name>
<etal>et al</etal>
</person-group>
<article-title>De novo FTL mutation: a clinical, neuroimaging, and molecular study</article-title>
<source>Mov Disord</source>
<year>2013</year>
<volume>28</volume>
<fpage>252</fpage>
<lpage>253</lpage>
<comment>doi:
<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1002/mds.25275">10.1002/mds.25275</ext-link>
</comment>
<pub-id pub-id-type="pmid">23239021</pub-id>
</element-citation>
</ref>
<ref id="b15">
<label>15</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chinnery</surname>
<given-names>PF</given-names>
</name>
<name>
<surname>Curtis</surname>
<given-names>ARJ</given-names>
</name>
<name>
<surname>Fey</surname>
<given-names>C</given-names>
</name>
<etal>et al</etal>
</person-group>
<article-title>Neuroferritinopathy in a French family with late onset dominant dystonia</article-title>
<source>J Med Genet</source>
<year>2003</year>
<volume>40</volume>
<fpage>e69</fpage>
<pub-id pub-id-type="pmid">12746423</pub-id>
</element-citation>
</ref>
<ref id="b16">
<label>16</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mancuso</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Davidzon</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Kurlan</surname>
<given-names>RM</given-names>
</name>
<etal>et al</etal>
</person-group>
<article-title>Hereditary ferritinopathy: a novel mutation, its cellular pathology, and pathogenetic insights</article-title>
<source>J Neuropathol Exp Neurol</source>
<year>2005</year>
<volume>64</volume>
<fpage>280</fpage>
<lpage>294</lpage>
<pub-id pub-id-type="pmid">15835264</pub-id>
</element-citation>
</ref>
<ref id="b17">
<label>17</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Maciel</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Cruz</surname>
<given-names>VT</given-names>
</name>
<name>
<surname>Constante</surname>
<given-names>M</given-names>
</name>
<etal>et al</etal>
</person-group>
<article-title>Neuroferritinopathy: missense mutation in FTL causing early-onset bilateral pallidal involvement</article-title>
<source>Neurology</source>
<year>2005</year>
<volume>65</volume>
<fpage>603</fpage>
<lpage>605</lpage>
<pub-id pub-id-type="pmid">16116125</pub-id>
</element-citation>
</ref>
<ref id="b18">
<label>18</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ohta</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Takiyama</surname>
<given-names>Y</given-names>
</name>
</person-group>
<article-title>MRI findings in neuroferritinopathy</article-title>
<source>Neurol Res Int</source>
<year>2012</year>
<volume>2012</volume>
<fpage>197438</fpage>
<comment>doi:
<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1155/2012/197438">10.1155/2012/197438</ext-link>
</comment>
<pub-id pub-id-type="pmid">21808735</pub-id>
</element-citation>
</ref>
<ref id="b19">
<label>19</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kubota</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Hida</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Ichikawa</surname>
<given-names>Y</given-names>
</name>
<etal>et al</etal>
</person-group>
<article-title>A novel ferritin light chain gene mutation in a Japanese family with neuroferritinopathy: description of clinical features and implications for genotype-phenotype correlations</article-title>
<source>Mov Disord</source>
<year>2009</year>
<volume>24</volume>
<fpage>441</fpage>
<lpage>445</lpage>
<comment>doi:
<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1002/mds.22435">10.1002/mds.22435</ext-link>
</comment>
<pub-id pub-id-type="pmid">19117339</pub-id>
</element-citation>
</ref>
<ref id="b20">
<label>20</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Devos</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Tchofo</surname>
<given-names>PJ</given-names>
</name>
<name>
<surname>Vuillaume</surname>
<given-names>I</given-names>
</name>
<etal>et al</etal>
</person-group>
<article-title>Clinical features and natural history of neuroferritinopathy caused by the 458dupA FTL mutation</article-title>
<source>Brain</source>
<year>2009</year>
<volume>132</volume>
<fpage>2008</fpage>
<lpage>2010</lpage>
</element-citation>
</ref>
<ref id="b21">
<label>21</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Moutton</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Fergelot</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Trocello</surname>
<given-names>JM</given-names>
</name>
<etal>et al</etal>
</person-group>
<article-title>A novel FTL mutation responsible for neuroferritinopathy with asymmetric clinical features and brain anomalies</article-title>
<source>Park Relat Disord</source>
<year>2014</year>
<volume>20</volume>
<fpage>935</fpage>
<lpage>937</lpage>
</element-citation>
</ref>
<ref id="b22">
<label>22</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nishida</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Garringer</surname>
<given-names>HJ</given-names>
</name>
<name>
<surname>Futamura</surname>
<given-names>N</given-names>
</name>
<etal>et al</etal>
</person-group>
<article-title>A novel ferritin light chain mutation in neuroferritinopathy with an atypical presentation</article-title>
<source>J Neurol Sci</source>
<year>2014</year>
<volume>342</volume>
<fpage>173</fpage>
<lpage>177</lpage>
<pub-id pub-id-type="pmid">24825732</pub-id>
</element-citation>
</ref>
<ref id="b23">
<label>23</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wills</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Sawle</surname>
<given-names>GV</given-names>
</name>
<name>
<surname>Guilbert</surname>
<given-names>PR</given-names>
</name>
<name>
<surname>Curtis</surname>
<given-names>ARJ</given-names>
</name>
</person-group>
<article-title>Palatal tremor and cognitive decline in neuroferritinopathy</article-title>
<source>J Neurol Neurosurg Psychiatry</source>
<year>2002</year>
<volume>73</volume>
<fpage>91</fpage>
<lpage>92</lpage>
<comment>doi:
<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1136/jnnp.73.1.91">10.1136/jnnp.73.1.91</ext-link>
</comment>
<pub-id pub-id-type="pmid">12082064</pub-id>
</element-citation>
</ref>
<ref id="b24">
<label>24</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Crompton</surname>
<given-names>DE</given-names>
</name>
<name>
<surname>Chinnery</surname>
<given-names>PF</given-names>
</name>
<name>
<surname>Bates</surname>
<given-names>D</given-names>
</name>
<etal>et al</etal>
</person-group>
<article-title>Spectrum of movement disorders in neuroferritinopathy</article-title>
<source>Mov Disord</source>
<year>2005</year>
<volume>20</volume>
<fpage>95</fpage>
<lpage>99</lpage>
<pub-id pub-id-type="pmid">15390132</pub-id>
</element-citation>
</ref>
<ref id="b25">
<label>25</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Caparros-Lefebvre</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Destee</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Petit</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>Late onset familial dystonia: could mitochondrial deficits induce a diffuse lesioning process of the whole basal ganglia system?</article-title>
<source>J Neurol Neurosurg Psychiatry</source>
<year>1997</year>
<volume>63</volume>
<fpage>196</fpage>
<lpage>203</lpage>
<pub-id pub-id-type="pmid">9285458</pub-id>
</element-citation>
</ref>
<ref id="b26">
<label>26</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ondo</surname>
<given-names>WG</given-names>
</name>
<name>
<surname>Adam</surname>
<given-names>OR</given-names>
</name>
<name>
<surname>Jankovic</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Chinnery</surname>
<given-names>PF</given-names>
</name>
</person-group>
<article-title>Dramatic response of facial stereotype/tic to tetrabenazine in the first reported cases of neuroferritinopathy in the United States</article-title>
<source>Mov Disord</source>
<year>2010</year>
<volume>25</volume>
<fpage>2470</fpage>
<lpage>2472</lpage>
<comment>doi:
<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1002/mds.23299">10.1002/mds.23299</ext-link>
</comment>
<pub-id pub-id-type="pmid">20818611</pub-id>
</element-citation>
</ref>
<ref id="b27">
<label>27</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lehn</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Boyle</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Brown</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Airey</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Mellick</surname>
<given-names>G</given-names>
</name>
</person-group>
<article-title>Neuroferritinopathy</article-title>
<source>Parkinsonism Relat Disord</source>
<year>2012</year>
<volume>18</volume>
<fpage>909</fpage>
<lpage>915</lpage>
<comment>doi:
<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.parkreldis.2012.06.021">10.1016/j.parkreldis.2012.06.021</ext-link>
</comment>
<pub-id pub-id-type="pmid">22818529</pub-id>
</element-citation>
</ref>
<ref id="b28">
<label>28</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Keogh</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Aribisala</surname>
<given-names>BS</given-names>
</name>
<name>
<surname>He</surname>
<given-names>J</given-names>
</name>
<etal>et al</etal>
</person-group>
<article-title>Voxel-based analysis in neuroferritinopathy expands the phenotype and determines radiological correlates of disease severity</article-title>
<source>J Neurol</source>
<year>2015</year>
<volume>262</volume>
<fpage>2232</fpage>
<lpage>40</lpage>
<comment>doi:
<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1007/s00415-015-7832-2">10.1007/s00415-015-7832-2</ext-link>
</comment>
<pub-id pub-id-type="pmid">26142024</pub-id>
</element-citation>
</ref>
<ref id="b29">
<label>29</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>McNeill</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Gorman</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Khan</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Horvath</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Blamire</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Chinnery</surname>
<given-names>PF</given-names>
</name>
</person-group>
<article-title>Progressive brain iron accumulation in neuroferritinopathy measured by the thalamic T2* relaxation rate</article-title>
<source>Am J Neuroradiol</source>
<year>2012</year>
<volume>33</volume>
<fpage>1810</fpage>
<lpage>1813</lpage>
<comment>doi:
<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.3174/ajnr.A3036">10.3174/ajnr.A3036</ext-link>
</comment>
<pub-id pub-id-type="pmid">22499840</pub-id>
</element-citation>
</ref>
<ref id="b30">
<label>30</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Batla</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Adams</surname>
<given-names>ME</given-names>
</name>
<name>
<surname>Erro</surname>
<given-names>R</given-names>
</name>
<etal>et al</etal>
</person-group>
<article-title>Cortical pencil lining in neuroferritinopathy: a diagnostic clue</article-title>
<source>Neurology</source>
<year>2015</year>
<volume>84</volume>
<fpage>1816</fpage>
<lpage>1818</lpage>
<pub-id pub-id-type="pmid">25832658</pub-id>
</element-citation>
</ref>
<ref id="b31">
<label>31</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ory-Magne</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Brefel-Courbon</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Payoux</surname>
<given-names>P</given-names>
</name>
<etal>et al</etal>
</person-group>
<article-title>Clinical phenotype and neuroimaging findings in a French family with hereditary ferritinopathy (FTL498-499InsTC)</article-title>
<source>Mov Disord</source>
<year>2009</year>
<volume>24</volume>
<fpage>1676</fpage>
<lpage>1683</lpage>
<comment>doi:
<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1002/mds.22669">10.1002/mds.22669</ext-link>
</comment>
<pub-id pub-id-type="pmid">19514068</pub-id>
</element-citation>
</ref>
<ref id="b32">
<label>32</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ohta</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Nagasaka</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Shindo</surname>
<given-names>K</given-names>
</name>
<etal>et al</etal>
</person-group>
<article-title>Neuroferritinopathy in a Japanese family with a duplication in the ferritin light chain gene</article-title>
<source>Neurology</source>
<year>2008</year>
<volume>70</volume>
<fpage>1493</fpage>
<lpage>1494</lpage>
<comment>doi:
<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1212/01.wnl.0000310428.74624.95">10.1212/01.wnl.0000310428.74624.95</ext-link>
</comment>
<pub-id pub-id-type="pmid">18413574</pub-id>
</element-citation>
</ref>
<ref id="b33">
<label>33</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Crompton</surname>
<given-names>DE</given-names>
</name>
<name>
<surname>Chinnery</surname>
<given-names>PF</given-names>
</name>
<name>
<surname>Fey</surname>
<given-names>C</given-names>
</name>
<etal>et al</etal>
</person-group>
<article-title>Neuroferritinopathy: a window on the role of iron in neurodegeneration</article-title>
<source>Blood Cells Mol Dis</source>
<year>2002</year>
<volume>29</volume>
<fpage>522</fpage>
<lpage>531</lpage>
<pub-id pub-id-type="pmid">12547246</pub-id>
</element-citation>
</ref>
<ref id="b34">
<label>34</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Keogh</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Singh</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Chinnery</surname>
<given-names>PF</given-names>
</name>
</person-group>
<article-title>Early neuropsychiatry features in neuroferritinopathy</article-title>
<source>Mov Disord</source>
<year>2013</year>
<volume>28</volume>
<fpage>1310</fpage>
<lpage>1313</lpage>
<comment>doi:
<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1002/mds.25371">10.1002/mds.25371</ext-link>
</comment>
<pub-id pub-id-type="pmid">23436236</pub-id>
</element-citation>
</ref>
<ref id="b35">
<label>35</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mir</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Edwards</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Curtis</surname>
<given-names>ARJ</given-names>
</name>
<name>
<surname>Bhatia</surname>
<given-names>KP</given-names>
</name>
<name>
<surname>Quinn</surname>
<given-names>NP</given-names>
</name>
</person-group>
<article-title>Adult-onset generalized dystonia due to a mutation in the neuroferritinopathy gene</article-title>
<source>Mov Disord</source>
<year>2005</year>
<volume>20</volume>
<fpage>243</fpage>
<lpage>245</lpage>
<pub-id pub-id-type="pmid">15390032</pub-id>
</element-citation>
</ref>
<ref id="b36">
<label>36</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>McNeill</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Birchall</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Hayflick</surname>
<given-names>SJ</given-names>
</name>
<etal>et al</etal>
</person-group>
<article-title>T2* and FSE MRI distinguishes four subtypes of neurodegeneration with brain iron accumulation</article-title>
<source>Neurology</source>
<year>2008</year>
<volume>70</volume>
<fpage>1614</fpage>
<lpage>1619</lpage>
<comment>doi:
<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1212/01.wnl.0000310985.40011.d6">10.1212/01.wnl.0000310985.40011.d6</ext-link>
</comment>
<pub-id pub-id-type="pmid">18443312</pub-id>
</element-citation>
</ref>
<ref id="b37">
<label>37</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Taly</surname>
<given-names>AB</given-names>
</name>
<name>
<surname>Meenakshi-Sundaram</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Sinha</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Swamy</surname>
<given-names>HS</given-names>
</name>
<name>
<surname>Arunodaya</surname>
<given-names>GR</given-names>
</name>
</person-group>
<article-title>Wilson disease</article-title>
<source>Medicine (Baltimore)</source>
<year>2007</year>
<volume>86</volume>
<fpage>112</fpage>
<lpage>121</lpage>
<pub-id pub-id-type="pmid">17435591</pub-id>
</element-citation>
</ref>
<ref id="b38">
<label>38</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Das</surname>
<given-names>SK</given-names>
</name>
<name>
<surname>Ray</surname>
<given-names>K</given-names>
</name>
</person-group>
<article-title>Wilson’s disease: an update</article-title>
<source>Nat Clin Pract Neurol</source>
<year>2006</year>
<volume>2</volume>
<fpage>482</fpage>
<lpage>493</lpage>
<pub-id pub-id-type="pmid">16932613</pub-id>
</element-citation>
</ref>
<ref id="b39">
<label>39</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Walker</surname>
<given-names>RH</given-names>
</name>
</person-group>
<article-title>Untangling the thorns: advances in the neuroacanthocytosis syndromes</article-title>
<source>J Mov Disord</source>
<year>2015</year>
<volume>8</volume>
<fpage>41</fpage>
<lpage>54</lpage>
<comment>doi:
<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.14802/jmd.15009">10.14802/jmd.15009</ext-link>
</comment>
<pub-id pub-id-type="pmid">26090076</pub-id>
</element-citation>
</ref>
<ref id="b40">
<label>40</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Martino</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Stamelou</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Bhatia</surname>
<given-names>KP</given-names>
</name>
</person-group>
<article-title>The differential diagnosis of huntington’s disease-like syndromes: “red flags” for the clinician</article-title>
<source>J Neurol Neurosurg Psychiatry</source>
<year>2013</year>
<volume>84</volume>
<fpage>650</fpage>
<lpage>656</lpage>
<comment>doi:
<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1136/jnnp-2012-302532">10.1136/jnnp-2012-302532</ext-link>
</comment>
<pub-id pub-id-type="pmid">22993450</pub-id>
</element-citation>
</ref>
<ref id="b41">
<label>41</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Walker</surname>
<given-names>RH</given-names>
</name>
</person-group>
<article-title>Chorea</article-title>
<source>Continuum (Minneap Minn)</source>
<year>2013</year>
<volume>19</volume>
<fpage>1242</fpage>
<lpage>1263</lpage>
<comment>doi:
<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1212/01.CON.0000436155.46909.c3">10.1212/01.CON.0000436155.46909.c3</ext-link>
</comment>
<pub-id pub-id-type="pmid">24092289</pub-id>
</element-citation>
</ref>
<ref id="b42">
<label>42</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Balint</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Bhatia</surname>
<given-names>KP</given-names>
</name>
</person-group>
<article-title>Isolated and combined dystonia syndromes—an update on new genes and their phenotypes</article-title>
<source>Eur J Neurol</source>
<year>2015</year>
<volume>22</volume>
<fpage>610</fpage>
<lpage>617</lpage>
<comment>doi:
<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1111/ene.12650">10.1111/ene.12650</ext-link>
</comment>
<pub-id pub-id-type="pmid">25643588</pub-id>
</element-citation>
</ref>
<ref id="b43">
<label>43</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Houlden</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Singleton</surname>
<given-names>AB</given-names>
</name>
</person-group>
<article-title>The genetics and neuropathology of Parkinson’s disease</article-title>
<source>Acta Neuropathol</source>
<year>2012</year>
<volume>124</volume>
<fpage>325</fpage>
<lpage>338</lpage>
<comment>doi:
<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1007/s00401-012-1013-5">10.1007/s00401-012-1013-5</ext-link>
</comment>
<pub-id pub-id-type="pmid">22806825</pub-id>
</element-citation>
</ref>
</ref-list>
</back>
</pmc>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Pmc/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000179 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd -nk 000179 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Canada
   |area=    ParkinsonCanadaV1
   |flux=    Pmc
   |étape=   Corpus
   |type=    RBID
   |clé=     PMC:4795517
   |texte=   Neuroferritinopathy: Pathophysiology, Presentation, Differential
Diagnoses and Management
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/RBID.i   -Sk "pubmed:27022507" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd   \
       | NlmPubMed2Wicri -a ParkinsonCanadaV1 

Wicri

This area was generated with Dilib version V0.6.29.
Data generation: Thu May 4 22:20:19 2017. Site generation: Fri Dec 23 23:17:26 2022